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Abstract 
  Accumulation of genetic mutation in cancer cells and extracellular stimuli, for 
instance, cytokines released from the microenvironment such as chronic inflammation 
surrounding cancer cells, seem to trigger dedifferentiation resulting in gaining of 
stemness or epithelial-mesenchymal transition (EMT). It is hypothesized that this 
transition from differentiated epithelial cells is critical for the progression, recurrence, 
and drug resistance of gastrointestinal and liver cancer. Therefore, it is important to 
study the mechanisms underlying the transition of differentiation status in epithelial 
cells in order to explore novel strategies for drug discovery in cancer.  
  In the first part of this work, the transition of differentiation status between 
stem/progenitor cells and hepatocytes, which are differentiated epithelial cells from the 
adult mouse liver, was investigated. Moreover, the contribution of autophagy to the 
mechanism for the alteration of differentiation status between the stem/progenitor cells 
and hepatocytes was assessed. Adult stem/progenitor cells were isolated from the livers 
of mice with chemically-induced liver injury. The effect of autophagy on hepatic 
differentiation was investigated by silencing the gene encoding autophagy protein 5 
(ATG5) using small interfering RNAs. ATG5 silencing suppressed autophagy as observed 
by decreased active microtubule-associated protein light chain 3 (LC3) and increased p62 
expression. Inhibition of autophagy promoted hepatic differentiation in the 
stem/progenitor cells. A mechanism suggested for the hepatic differentiation induced by 
inhibiting autophagy was the accumulation of intracellular p62 protein and activation of 
the mammalian target of rapamycin pathway by amino acids. 
  In the second part, I investigated the role of the Notch ligand, Jagged 1 (JAG1), and 
EMT in the prognosis and recurrence of human subjects with colorectal cancer (CRC). 
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The protein expression of JAG1 in CRC specimens was examined using 
immunohistochemistry. Moreover, EMT in CRC was evaluated based on the decreased 
protein expression levels of the well-differentiated epithelial cell marker, E-cadherin, 
using immunohistochemistry. The correlation of JAG1 expression with overall survival 
(OS), relapse-free survival (RFS), and E-cadherin expression was analyzed. JAG1 
expression in cancerous tissues was graded as weak, moderate, or strong and higher 
JAG1 expression was associated with poorer prognostic outcomes. A correlation 
between high intensity of JAG1 staining and a low population of E-cadherin-positive 
cancer cells was detected in the analysis of JAG1 and E-cadherin expression. A 
mechanism for high JAG1 expression and EMT induction in CRC was suggested based 
on the significant correlation observed between JAG1 expression and KRAS status in 
groups stratified by high E-cadherin expression. In vitro studies using a colon cancer 
cell line supported the results from the human studies. Gene silencing using siRNA 
against JAG1 (siJAG1) indicated that JAG1 promotes EMT. An investigation using an 
MEK inhibitor suggested that the RAS-MEK-MAP pathway positively regulates JAG1 
expression and EMT.  
Taken together, I propose that suppression of autophagy and JAG1-Notch-related 
signaling could revert dedifferentiated epithelial cancer cells to a well-differentiated 
status in the gastrointestinal tract and in liver cancer. Further, elucidation of these 
regulation mechanisms for the transition of differentiation status in epithelial cells could 
lead to the discovery of new drug candidates to prevent the progression, recurrence, 
drug resistance, or metastasis of gastrointestinal and liver cancer. 
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Abbreviations 
 
18s rRNA 18s ribosomal RNA  
3-MA 3-methyladenine 
AF Alexa Fluor 
ALB albumin 
ALK anaplastic lymphoma kinase  
Apc adenomatous polyposis coli  
APC allophycocyanin 
ATG5 autophagy-related gene 5 
BCAA branched chain amino acid 
CD cluster of differentiation 
CI confidence interval  
CK cytokeratin 
CLiPs chemically induced liver stem/progenitor cells 
CMS consensus molecular subtype 
CRC colorectal cancer 
CSC cancer stem cell 
DDC 3,5-diethoxycarbonyl-1,4-dihydrocollidine 
DLL delta-like ligand 
DMSO dimethylsulfoxide 
EGF epidermal growth factor 
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EMT-TF EMT-inducing transcription factors 
ERK extracellular signal-regulated kinase 
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4 
 
JAG Jagged 
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miRNA micro-RNA 
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mTOR mammalian target of rapamycin 
mTORC mTOR complex 
NICD notch intracellular domain 
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NS nonspecific 
NF nuclear factor 
OS overall survival 
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oval-cell-like cells similar to oval cells 
p53KO p53−/− cells 
pAKT phosphorylated AKT 
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PCR polymerase chain reaction 
PDGF platelet-derived growth factor 
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pERK phosphorylated ERK 
PI3K phosphoinositide 3-kinase 
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qRT-PCR quantitative RT-PCR 
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S.D. standard deviations 
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siJAG1 siRNA against JAG1 
siSQSTM1/p62 siRNA against SQSTM1/p62 
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siNON non-targeting siRNA 
siRNA Small interfering RNA 
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TP53 tumor protein p53 
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General Introduction 
  Treatment strategies for human cancers such as surgery, drug treatment, radiotherapy, 
and a combination of these frequently produce failed results in clinical cases. Drug 
resistance and/or radioresistance, tumor recurrence, and metastasis are considered as the 
major reasons for treatment failure. Increasing evidence has shown that cancer stem 
cells (CSCs) are the root causes of tumor formation and recurrence (Gupta et al., 2009; 
Sato et al., 2016; Suresh et al., 2016; Zeuner et al., 2014). Moreover, 
epithelial-mesenchymal transition (EMT) plays a significant role in cancer progression. 
The acquisition of invasiveness in epithelial cancer cells is thought to be the first step 
that eventually leads to metastatic dissemination with life-threatening consequences. 
Activation of the EMT program has been proposed as the critical mechanism for the 
acquisition of an invasive phenotype and the subsequent systemic spread of epithelial 
cancer cells (Nieto, 2013; Sato et al., 2016; Thiery, 2002; Zheng and Kang, 2014). 
Therefore, to overcome the failed outcome and improve the efficacy of traditional 
anticancer therapies, it is important to understand the regulatory mechanisms underlying 
CSCs and EMT related processes.  
  The adult liver contains two main epithelial cell types, the hepatocytes and the bile 
duct epithelial cells. In the normal state without injury, cell turnover is very slow 
(Magami et al., 2002; Malato et al., 2011; Sell, 2001). However, the liver is a highly 
regenerative organ and can completely restore its mass after injury (Michalopoulos and 
DeFrances, 1997). The liver has been proposed to possess facultative stem cells that can 
become activated if any injury impairs the replication ability of the mature cells, 
particularly hepatocytes (Miyajima et al., 2014). These facultative stem cells are 
believed to exist near the portal region of the hepatic lobule in the canal of Hering 
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(Theise et al., 1999). After activation, these stem cells are thought to proliferate and 
produce progenitor cells called “oval cells,” which then differentiate into functional 
mature hepatocytes.  
  A previous study showed that Notch and Wnt are required for the differentiation of 
liver stem/progenitor cells (LPCs), and that their interaction is necessary for the 
appropriate delineation of hepatocellular versus biliary fate (Boulter et al., 2012). 
During the activation of LPCs in biliary disease, LPCs express Notch receptors, which 
are activated through interaction with Jagged 1 (JAG1) expressed by the surrounding 
fibroblasts.  
  The ductular reaction that occurs at the periphery of portal tracts is a response to the 
injury observed in liver diseases, including hepatitis C virus infection (Lowes et al., 
1999). In chronic human liver disease, ductular proliferations containing cells similar to 
oval cells (oval-cell-like) are found frequently (Clouston et al., 2005; Richardson et al., 
2007). Some recent experiments in mice indicated that oval-cell-like cells are 
transdifferentiated from hepatocytes through Notch-mediated cell lineage conversion 
rather than having a biliary origin (Sekiya and Suzuki, 2014; Tarlow et al., 2014; Yanger 
et al., 2013; Yimlamai et al., 2014). Thus, during oval-cell-inducing injury, hepatocytes 
could produce cells similar to LPCs if the injury was long-lived. Moreover, 
hepatocyte-derived-LPCs like cells have recently been shown to be capable of 
self-renewal, as well as differentiation into functional hepatocytes (Tarlow et al., 2014). 
This ductular plasticity of hepatocytes is also relevant to liver cancer, particularly 
cholangiocarcinoma (Deugnier et al., 1993; Prior, 1988; Tsukuma et al., 1993), which in 
the past was thought to be derived from proposed hepatic stem cells, but can in fact 
originate from hepatocytes (Fan et al., 2012; Sekiya and Suzuki, 2012). Thus, 
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identification of the signals that control cell plasticity transiting between a 
well-differentiated and a stem-like state in the liver, seems important to develop 
strategies for cancer therapy (Katsuda et al., 2017; Tarlow et al., 2014; Yimlamai et al., 
2014). 
  To investigate liver cancers that are relevant to ductular reaction, experimental rodent 
models have been developed with chronic liver injury induced by potential carcinogens, 
including choline-deficient/ethionine-containing and 3,5-diethoxycarbonyl- 
1,4-dihydrocollidine (DDC)-containing diets (Preisegger et al., 1999; Shinozuka et al., 
1978). In these models, biliary lineage cells that include oval cells appear and 
proliferate around the portal veins to regenerate the damaged liver tissues. Moreover, 
previous studies using these rodent models of chronic liver injury demonstrated their 
utility to study the progression of human primary liver cancers (Dumble et al., 2002; 
Suzuki et al., 2008). Thus, to develop therapeutic strategies for liver diseases, it is 
important to understand how oval-cell-containing biliary lineage cells emerge during the 
ductular reaction and contribute to the progression of chronic liver disease and liver 
cancer in these chronic liver injury models.  
  Autophagy, a process of degrading and recycling proteins and damaged cellular 
organs, has been shown to protect cells from nutritional deficiency and prevent cell 
death. Multiple studies have closely linked autophagy to many disease processes, 
especially cancers (Galluzzi et al., 2016; Gu et al., 2014; Lei et al., 2017; Li et al., 2017; 
Song et al., 2013). CSCs have characteristics similar to normal stem cells, such as 
self-renewal and differentiation. Autophagy might be involved in stemness maintenance 
of CSCs. Recently, researchers noted that elevated autophagic flux in CSCs could 
maintain metabolic homeostasis and cell viability, which facilitated CSCs to resist 
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microenvironmental stresses such as hypoxia, starvation, or anticancer treatment. Some 
studies found that inhibiting autophagy might be responsible in part, for the 
downregulation of stem cell markers, enhanced sensitivity to chemotherapeutics, and 
inhibition of CSCs self-renewal (Berardi et al., 2016; Zhang et al., 2016; Zhang et al., 
2017). Thus, a pro-survival autophagic pathway may be critical for CSCs maintenance.  
  The aim of the present study was to investigate the role of autophagy inhibition and 
the related mechanism for hepatic differentiation from facultative LPCs or cells similar 
to LPCs potentially derived from mature hepatocytes collected from the liver during 
oval-cell inducing injury in a rodent model of chronic liver injury. I then discuss the role 
of autophagy and the related mechanism for maintaining stemness and cell plasticity 
transiting between stem/progenitor cells and differentiated cells.  
  Carcinogenesis arises from a series of genetic/epigenetic alterations and interactions 
with the microenvironment and growth factors that transform the normal intestinal 
mucosa into an aberrant phenotype (Becht et al., 2016; Carethers and Jung, 2015; 
Lampropoulos et al., 2012; Linnekamp et al., 2015; Markowitz and Bertagnolli, 2009; 
Zeuner et al., 2014). Tumor heterogeneity can be explained by the assembly of random 
genetic abnormalities as well as varying microenvironmental influences. A diverse 
population of subclones with different characteristics arises simultaneously. However, 
only selected clones can accumulate further mutations, resulting in a varying metastatic 
tumor from the primary lesion.  
  Intestinal homeostasis is regulated by the crosstalk of evolutionarily conserved 
pathways such as Wnt, Notch, and Hedgehog, which control the balance between 
proliferation, differentiation, migration, and renewal. Notch signaling is associated with 
multiple aspects of cancer biology (Espinoza and Miele, 2013). This pathway comprises 
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five canonical Notch ligands (Delta-like ligand 1 [DLL1], DLL3 and DLL4, and JAG1 
and JAG2) and four Notch receptor paralogues (Notch1 – 4) (Gu et al., 2012). Unlike 
the DLL1/4 ligands, JAG1 was found to be dispensable for the homeostasis of normal 
intestinal stem cells (Pellegrinet et al., 2011); however, JAG1 has been shown to 
participate in multiple aspects of cancer biology including tumor angiogenesis, 
neoplastic cell growth, CSCs, EMT, the metastatic process, and resistance to therapy in 
several types of cancer. Importantly, JAG1 expression can be induced by signaling 
pathways such as transforming growth factor-β (TGF-β), Wnt-β-catenin, Interleukin-6 
(IL-6), and Nuclear factor-κB (NF-κB), as well as by the Notch pathway itself (Chen et 
al., 2010; Rodilla et al., 2009; Sansone et al., 2007; Yamamoto et al., 2013; Zavadil et 
al., 2004).  
  The abilities of tumor cells to invade the surrounding tissues and to colonize distant 
organs (metastatic process) are key features of aggressive cancers. In order to escape 
their severe local environment, epithelial cells can use the reversible developmental 
program EMT, during which epithelial features are suppressed and mesenchymal traits 
acquired thus transforming tumor cells into cells with the potential for invasion, 
resisting apoptosis, dissemination, and acquiring stem cell features (Hanahan and 
Weinberg, 2011; Kong et al., 2011; Lamouille et al., 2014; Zheng and Kang, 2014). 
Several reports have described JAG1 involvement in EMT, invasive potential, and 
metastasis (Dai et al., 2014; Kim et al., 2013; Leong et al., 2007; Tanaka et al., 2012). 
Overall, JAG1-induced Notch signaling appears to be implicated in different steps of 
the invasive/metastatic process.  
  EMT is a biologic process that allows a polarized epithelial cell to undergo multiple 
biochemical changes enabling it to assume a mesenchymal cell phenotype. A number of 
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varying molecular processes are engaged in order to initiate an EMT and enable its 
completion. These include activation of transcription factors, expression of specific 
cell-surface proteins, reorganization and expression of cytoskeletal proteins, production 
of extracellular matrix-degrading enzymes, and changes in the expression of specific 
microRNAs (Kalluri and Weinberg, 2009). The full spectrum of signaling mediators that 
contribute to EMT in carcinoma cells remains unclear. One hypothesis is that the 
genetic and epigenetic alterations undergone by cancer cells during the course of 
primary tumor formation render them responsive to EMT-inducing signals derived from 
tumor-associated stroma. In many carcinomas, EMT-inducing signals released from the 
tumor-associated stroma, notably hepatocyte growth factor (HGF), epidermal growth 
factor (EGF), platelet-derived growth factor (PDGF), and TGF-β, appear to play a 
significant role in the induction or functional activation of a series of EMT-inducing 
transcription factors (EMT-TFs) like Snail, Slug, Zinc finger E-box-binding homeobox 
1 (ZEB1), and Twist in cancer cells (Kokudo et al., 2008; Medici et al., 2008; Niessen et 
al., 2008; Shi and Massague, 2003; Thiery, 2002). The actual execution of the EMT 
program depends on a series of intracellular signaling networks involving 
signal-transducing proteins such as extracellular signal-regulated kinase (ERK), 
mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K), AKT, 
SMADs, β-catenin, and RAS as well as cell surface proteins such as β4 integrins (Tse 
and Kalluri, 2007). EMT-associated changes in gene expression are mediated by 
EMT-TFs, all of which suppress the expression of E-cadherin. Conversely, EMT-TFs 
activate the expression of mesenchyme-associated genes such as those encoding 
N-cadherin, fibronectin, and vimentin.  
  The aim of the study in the second part was to investigate the role of the JAG1-Notch 
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pathway and EMT in poor prognosis and recurrence in colorectal cancer (CRC). I then 
discuss the role of JAG1-Notch pathway and EMT as an underlying mechanism for 
cancer progression and recurrence. I also discuss the contribution of major genetic 
changes, which are acquired by genetic mutations, and the promoted or suppressed 
activity of various signaling pathway to JAG1 expression/EMT in CRC.   
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Chapter 1: Role of Autophagy and p62 for Hepatic 
differentiation in Adult Liver Stem/Progenitor Cells 
 
1.  Abstract 
Autophagy is a homeostatic process regulating the turnover of impaired proteins and 
organelles, and p62 (sequestosome-1, SQSTM1) functions as the autophagic receptor in 
this process. p62 also functions as a hub for intracellular signaling as in the mammalian 
target of rapamycin (mTOR) pathway. Liver stem/progenitor cells have the potential to 
differentiate into hepatocytes or cholangiocytes. In this study, I examined the effects of 
autophagy, p62, and associated signaling pathways on hepatic differentiation. Adult 
stem/progenitor cells were isolated from the livers of mice with chemically-induced liver 
injury. The effects of autophagy, p62, and related signaling pathways on hepatic 
differentiation were investigated by silencing the genes for autophagy protein 5 (ATG5) 
and/or SQSTM1/p62 using small interfering RNAs. Hepatic differentiation was assessed 
based on increased albumin and hepatocyte nuclear factor 4α as hepatocyte markers, and 
decreased cytokeratin 19 and SOX9 as stem/progenitor cell markers. These markers were 
measured using quantitative RT-PCR, immunofluorescence, and western blotting. ATG5 
silencing decreased the active LC3 and increased p62 levels, indicating the inhibition of 
autophagy. Inhibition of autophagy promoted hepatic differentiation in the 
stem/progenitor cells. Conversely, SQSTM1/p62 silencing impaired hepatic 
differentiation. A suggested mechanism for p62-dependent hepatic differentiation in my 
study was the activation of mTOR pathway by amino acids. Amino acid activation of 
mTOR signaling was enhanced by ATG5 silencing and suppressed by SQSTM1/p62 
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silencing. My findings indicate that promoting the amino acid sensitivity of the mTOR 
pathway is dependent on p62 accumulated by the inhibition of autophagy and that this 
process plays an important role in the hepatic differentiation of stem/progenitor cells. 
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2.  Introduction 
Mammalian target of rapamycin (mTOR) is a nutrition sensor and a key molecule 
regulating autophagy. Suppressed mTOR activity in an environment of poor nutrition 
activates autophagy-related pathways. Autophagy plays an important role in maintaining 
intracellular homeostasis by regulating the turnover of impaired proteins and organelles 
(Mizushima and Komatsu, 2011). Autophagosome formation is the first step of the 
autophagy process, with autophagosomes engulfing abnormal protein aggregates or 
damaged organelles and fusing with lysosomes to form mature autolysosomes. The 
proteins sequestered in autolysosomes are the digested to amino acids by lysosomal 
enzymes (Kaur and Debnath, 2015). Through autophagy, intracellular proteins and 
organelles are reorganized and intracellular energy homeostasis is maintained. 
The autophagic adaptor protein, p62 (sequestosome 1, SQSTM1), functions as an 
autophagy receptor for impaired proteins and organelles and is degraded along with these 
intracellular constituents in the autolysosome during the selective autophagic process 
(Rogov et al., 2014). Consistent with this, inhibition of autophagy induced intracellular 
p62 accumulation and the increased levels of p62 led to activation of p62-related 
signaling such as the Kelch like ECH associated protein 1 (KEAP1)–NF-E2-related 
factor 2 (NRF2) pathway (Komatsu et al., 2010). p62 was reported to regulate aspects of 
intracellular signaling such as the amino acid sensitivity of mTOR signaling activation 
(Duran et al., 2011). However, the physiological or pathological roles of mTOR 
activation through p62 have not been fully elucidated except for its involvement in cancer 
cell proliferation (Duran et al., 2011; Linares et al., 2015; Linares et al., 2013). 
mTOR is a serine/threonine kinase, a master regulator that couples amino acid 
availability to cell proliferation and autophagy (Jewell et al., 2013). Leucine and 
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glutamine in particular, are potent mTOR stimulators, and detailed mechanisms of amino 
acid-induced mTOR activation have been described (Duran et al., 2011; Duran et al., 
2012; Jewell et al., 2015). Under nutrient-rich conditions, mTOR promotes cell 
proliferation by stimulating biosynthetic pathways including protein synthesis and by 
inhibiting cellular catabolism through mechanisms such as repression of the autophagy 
pathway. 
In the liver, mTOR activation by amino acids was shown to be important for the 
synthesis and secretion of albumin in hepatocytes (Ijichi et al., 2003; Okuno et al., 1995). 
In other reports, activation of mTOR signaling significantly affected the liver 
regeneration processes through the replication of hepatocytes in the liver (Espeillac et al., 
2011; Zhang et al., 2015).  
Although proliferation of hepatocytes is essential for liver regeneration after 
hepatectomy, proliferation and differentiation of LPCs are also implicated as important 
for supplying multiple cellular components to the mature organs during recovery from 
severe liver injury (Duncan et al., 2009; Turner et al., 2011). The liver contains two types 
of epithelial cells, hepatocytes and cholangiocytes. When the replication capacities of 
hepatocytes and/or cholangiocytes are exhausted, adult LPCs may be activated to supply 
these cell types (Furuyama et al., 2011; Huch et al., 2013). 
A previous study in the laboratory to which I belonged, demonstrated the role of 
autophagy in liver regeneration after partial hepatectomy and the function of hepatocytes, 
using liver-specific knockouts of autophagy-related gene 5 (ATG5) (Toshima et al., 2014). 
However, the role of autophagy in LPCs has not been addressed yet. 
Therefore, this study aimed to investigate the association of autophagy with hepatocyte 
differentiation in LPCs. This goal included elucidating the role of p62, and its associated 
17 
 
mTOR signaling in hepatic differentiation induced by autophagy inhibition. 
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3.  Materials and Methods 
3.1. Mouse experiments 
Male C57BL/6 mice (Charles River, Yokohama, Japan) were maintained in a specific 
pathogen-free facility with a 12 h dark/light cycle. Mice, beginning at 8 wk of age, were 
fed a diet containing 0.1% DDC (Tokyo Chemical Industry, Tokyo, Japan) for 1 to 3 wk to 
induce the ductular reaction (Dorrell et al., 2011; Kitade et al., 2013; Okabe et al., 2009). 
All animal experiments were approved by the Kyushu University Animal Experiment 
Committee (A25-029, A27-248) and the care of the animals was in accordance with 
institutional guidelines. 
3.2. Isolation of Epithelial cell adhesion molecule (EPCAM)+ Cluster of 
differentiation (CD)133Low cells 
DDC-injured livers from the mice were digested using a two-step collagenase 
perfusion method. After eliminating hepatocytes by centrifugation at 50 ×g for 1 min, the 
cell suspension was centrifuged at 200 ×g for 5 min (fraction 1). The tissue remaining 
after two-step collagenase perfusion was further digested in collagenase solution. The 
cell suspension was centrifuged at 200 ×g for 5 min (fraction 2). The tissue remaining 
after digestion in collagenase solution was digested in collagenase/Accutase solution. 
The cell suspension was centrifuged at 200 ×g for 5 min (fraction 3). Cells derived from 
fractions 1, 2 and 3 were combined and treated with an anti-FcR antibody (BioLegend, 
San Diego, CA, USA) followed by incubation with an Alexa Fluor 488 
(AF488)-conjugated anti-CD133 antibody (BD Biosciences, Franklin Lakes, NJ, USA), 
mouse lineage cocktail antibodies containing anti-CD3c, anti-CD11b, anti-CD45R, 
anti-TER-119 and anti-LY-6C/6G conjugated to biotin (BioLegend) and an 
allophycocyanin (APC)-conjugated anti- EPCAM antibody (BD Biosciences). Next, 
biotin-conjugated antibodies were labeled with phycoerythrin (PE)-conjugated 
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streptavidin (BD Biosciences). Lineage-negative, EPCAM+ and CD133High or Low cells 
were isolated by fluorescence-activated cell sorting (FACS) using a FACS Aria II (BD 
Biosciences) or a SH800 (Sony, Tokyo, Japan). The antibodies used are detailed in Table 
1- 1. 
3.3. Cell culture and differentiation 
  Cells were seeded on collagen I-coated plastic dishes (AGC Techno Glass, Shizuoka, 
Japan) and cultured in William’s E medium containing 10% fetal bovine serum, 10 mM 
HEPES, 1.25 mM N-acetylcysteine, 10−7 M dexamethasone, 1× insulin-transferrin- 
selenium (ThermoFisher Scientific, Waltham, MA, USA), 10 mM nicotinamide, 50 
ng/mL murine EGF and 50 ng/mL murine HGF to maintain clonal proliferation (Dorrell 
et al., 2011; Kamiya et al., 2009; Kitade et al., 2013; Okabe et al., 2009). 
Cells were subjected to differentiation toward hepatocytes, as previously described, but 
with modifications (Kitade et al., 2013; Okabe et al., 2009). Briefly, cells were plated at 
50% confluence on a plastic tissue culture plate in standard culture medium. After 2 d, 20 
ng/mL murine oncostatin M (OSM) and 1% dimethylsulfoxide (DMSO) were added to 
the confluent culture. On days 4 and 8 after plating, cells were treated with standard 
culture medium containing 20 ng/mL OSM, 1% DMSO and 5% Matrigel (growth 
factor-reduced, ThermoFisher Scientific). Then, at 2 wk after plating, the cultured cells 
were subjected to various analyses. 
3.4. Small interfering RNA studies 
  Small interfering RNA (siRNA) studies were performed using the following siRNAs: 
ATG5 siRNA (ThermoFisher Scientific; oligo ID MSS247019, MSS247021), 
SQSTM1/p62 siRNA (ThermoFisher Scientific; oligo ID MSS207329) or nonspecific 
(NS) small interfering RNA (siRNA; ThermoFisher Scientific oligo ID 12935–300). The 
siRNAs were transfected into cells using Lipofectamine RNAiMAX transfection regent 
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(ThermoFisher Scientific), administering them at 1 d before, on the same day, and at 4 
and 8 d after the initiation of treatment, to induce hepatic differentiation. No signs of cell 
damage were observed following treatment with transfection reagent alone or the siRNAs 
transfection preparation (Figure 1- 5b). 
3.5. Gene expression analysis 
  Total RNA was extracted from cultured cells or frozen liver tissue using an RNeasy 
Mini Kit (QIAGEN, Hilden, Germany) and reverse-transcribed using SuperScript III 
(ThermoFisher Scientific) following the manufacturers' instructions. Quantitative 
RT-PCR (qRT-PCR) was performed using TaqMan enzyme and a StepOne plus PCR 
system (Applied Biosystems, Waltham, MA, USA). The probes used are detailed in 
Table 1- 2. Expression levels were normalized to values for 18s ribosomal RNA (18s 
rRNA). 
3.6. Western blot analysis 
  Liver tissue or cells were lysed in RIPA buffer. Lysate proteins were separated by SDS 
polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride 
membranes. The membranes were washed, blocked and incubated with primary 
antibodies, as indicated. After washing, membranes were incubated with the appropriate 
horseradish peroxidase-conjugated secondary antibody. The immunoreactive bands were 
visualized by enhanced chemiluminescence (Chemi-Lumi One Ultra: Nakarai Tesque, 
Kyoto, Japan) using an LAS3000 (Fuji Photo Film, Tokyo, Japan) or Amersham Imager 
600 (GE Healthcare, Little Chalfont, UK). The relative densities of immunoreactive 
bands were determined using ImageJ software (National Institute of Health, Bethesda, 
MD, USA). The antibodies used are detailed in Table 1- 1. 
3.7. Immunofluorescence analysis 
Liver tissues isolated from normal- or DDC-fed mice were embedded in O.C.T. 
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compound (Sakura Finetek, Torrance, CA, USA) and frozen sections were prepared using 
a CM3050s cryostat (Leica Biosystems, Nussloch, Germany). Frozen sections were fixed 
in phosphate buffered saline (PBS) containing 3% paraformaldehyde at room temperature 
for 5 min. After permeabilization with 0.3% Triton X-100 and blocking with 3% bovine 
serum albumin, sections were incubated with primary antibodies listed in Supplementary 
Table S2 followed by Alexa Fluor dye-conjugated secondary antibodies (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA). To stain cells, they were first 
fixed in 90% methanol at 4°C for 30 min and then treated as described above for staining 
sections. Fluorescence images were obtained using a Biorevo BZ-900 microscope 
(Keyence, Osaka, Japan), an ImageXpress (Molecular Devices, Sunnyvale, CA, USA) 
and an A1Rsi confocal laser microscope (Nikon, Tokyo, Japan). Images were analyzed 
using MetaXpress Software (Molecular Devices). The antibodies used are detailed in 
Table 1- 1. 
3.8. Statistical analysis 
All values are presented as the means ± standard deviations (S.D.), with between-group 
differences assessed by Student’s t-test. Statistical significant differences between groups 
were defined as **, P < 0.01 and *, P < 0.05. 
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4.  Results 
4.1. Isolation of adult LPCs from DDC-injured liver and generation of LPC lines 
EPCAM was used as a marker for LPCs (Okabe et al., 2009). The DDC diet induced liver 
injury with a ductular reaction, causing EPCAM+ cytokeratin 19 (CK19)+ LPCs to be 
activated and expanded (Figure 1- 1a, Figure 1- 2a). Consistent with the expansion of 
EPCAM+ CK19+ cells in injured liver, EPCAM and KRT19 mRNA expression increased 
and reached almost maximum expression at 2–3 wk after initiation of DDC treatment 
(Figure 1- 1b). LPC lines were generated from the livers of mice in which LPCs had been 
activated by consumption of the DDC diet for 3 wk. Primary LPCs were isolated at high 
purity by FACS after co-staining with cell-specific anti-EPCAM, anti-CD133 and lineage 
cocktail antibodies to exclude cells of hematopoietic origin (Figure 1- 1c). The 
“EPCAM+/CD133high or CD133low/Lineage-” cells were then cultured (Figure 1- 1d). This 
enabled us to obtain CK19-positive LPCs with self-renewing capacity and hepatic 
differentiation potential, the latter illustrated by increased levels of albumin, a 
hepatocyte-specific marker, and decreased CK19, a cholangiocytic or progenitor marker. 
These markers were determined by immunofluorescence (Figure 1- 1e), qRT-PCR 
(Figure 1- 2b) and western blotting (Figure 1- 2c) in cells cultured under the 
differentiation conditions. Only cells derived from EPCAM+/CD133low/Lineage- cells 
had hepatic differentiation potential (Figure 1- 1e, Figure 1- 2b and c); those derived from 
EPCAM+/CD133high/ Lineage- cells did not (data not shown).  
4.2. Inhibition of autophagy by ATG5 silencing induced hepatic differentiation 
  First, the effect of the autophagy inhibitor, 3-methyladenine (3-MA) (Seglen and 
Gordon, 1982), on hepatic differentiation in LPCs was examined (Figure 1- 3). Treatment 
of LPCs with 3-MA promoted hepatic differentiation, in a concentration-dependent 
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manner, as shown by increased albumin and hepatocyte nuclear factor 4α (HNF4α) and 
decreased CK19, by immunofluorescence. Next, to clarify the relationship between 
autophagy inhibition and hepatic differentiation, siRNAs against autophagic factor ATG5 
(siATG5) were utilized to inhibit autophagy (Fujita et al., 2011; Ishida et al., 2009; 
Toshima et al., 2014). ATG5 expression was decreased by siATG5, compared with 
non-targeting siRNA (siNON), treatment. siATG5 also inhibited autophagy, as indicated 
by decreased microtubule-associated protein light chain 3 (LC3) active form (lower band) 
and increased p62 (Figure 1- 4) levels. Inhibition of autophagy induced a hepato-like 
phenotype in LPCs, as indicated by increased albumin and decreased CK19 by western 
blotting (Figure 1- 4), increased albumin and HNF4α by immunofluorescence (Figure 1- 
5a, Figure 1- 6) and morphological appearance (Figure 1- 5b). ATG5 silencing and 
inhibition of autophagy were maintained for 2 wk in cells under the differentiation 
conditions (Figure 1- 5c and d). The effects of siATG5 in promoting hepatic 
differentiation appeared at 5 d after initiation of treatment.  
4.3. Autophagic adaptor protein p62 was significantly involved in hepatic 
differentiation 
Inhibition of autophagy by siATG5 induced intracellular accumulation of p62 (Figure 
1- 7a and Figure 1- 4). By immunofluorescence, HNF4α-positive differentiated 
hepatocytes had more intracellular p62 protein than CK19-positive 
differentiation-deficient cells, under siNON treatment (Figure 1- 7a). Furthermore, 
siATG5 treatment induced an increased number of p62- and HNF4α-double-positive cells 
(Figure 1- 7a).  
To determine the contribution of p62 to hepatic differentiation in LPCs, the effects of 
siRNA against SQSTM1/p62 (siSQSTM1/p62) were investigated. Decreased SQSTM1 
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mRNA expression was observed at 2 wk after siSQSTM1/p62 treatment under the 
differentiation conditions (Figure 1- 7b). siSQSTM1/p62 suppressed mRNA expression of 
albumin (ALB) and fructose-1,6-bisphosphatase 1 (FBP1), both hepatocyte markers. In 
contrast, siSQSTM1/p62 increased mRNA expression of KRT19 and SOX9, as progenitor 
and cholangiocyte markers, respectively (Figure 1- 7b). These results suggested that 
hepatic differentiation was impaired by p62 deficiency. Lower levels of p62 protein in 
cells treated with siSQSTM1/p62, compared with siNON, were associated with lower 
levels of albumin (Figure 1- 7d, Figure 1- 8b).  
Immunofluorescence analysis also revealed that p62 existed primarily in the 
differentiated hepato-like cells, as indicated by their staining for the hepatocyte marker 
HNF4α, under siNON treatment (Figure 1- 7c). siSQSTM1/p62 decreased intracellular 
p62 protein levels and also decreased the numbers of HNF4α- and albumin-positive cells 
(Figure 1- 7c, Figure 1- 8a and b). Quantitative fluorescence analysis showed that 
siSQSTM1/p62 decreased p62 and albumin levels and increased CK19 levels (Figure 1- 
8c). These results indicated that SQSTM1/p62 silencing impaired or delayed hepatic 
differentiation.  
siATG5 induced hepatic differentiation, as indicated by upregulation of albumin and 
downregulation of SOX9. Increased p62 was also observed (Figure 1- 7d). with siATG5 
treatment. ATG5 and SQSTM1/p62 were double-knocked down by siRNAs to determine 
whether hepatic differentiation induced by autophagy inhibition was dependent on p62 
levels (Figure 1- 7d). Co-treatment of cells with siATG5 and siSQSTM1/p62 reduced 
ATG5 and p62 expression. siRNA co-treatment also led to lower albumin levels than with 
single siATG5 treatment. In contrast, the liver progenitor and cholangiocyte marker 
SOX9 showed the opposite changes with siRNAs co-treatment compared with single 
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siATG5 treatment. Albumin and SOX9 levels were similar with double siRNA as with 
siNON treatment. This showed that hepatic differentiation of LPCs was impaired or 
delayed by double knockdown of ATG5 and SQSTM1/p62, more than with the single 
ATG5 knockdown. That is, intracellular p62 levels influenced hepatic differentiation. 
4.4. mTOR signaling activation was important for hepatic differentiation. 
Western blot analysis showed increased p62 and albumin levels in cells treated with 
siATG5 under hepatic differentiation conditions (Figure 1- 7d and Figure 1- 9a). 
Activation of mTOR signaling was observed in these cells, as indicated by increasing 
levels of phosphorylated ribosomal S6 protein (pS6) under the hepatic differentiation 
conditions (Figure 1- 7d and Figure 1- 9a). PI3k–AKT signaling was decreased and MAP 
kinase signaling was nearly unchanged, compared with siNON treatment, as indicated by 
phosphorylated AKT (pAKT) and phosphorylated ERK (pERK), respectively (Figure 1- 
9a). Conversely, under hepatic differentiation-deficient conditions induced with 
siSQSTM1/p62 treatment, p62 and albumin levels were decreased (Figure 1- 7d and 
Figure 1- 9a). siSQSTM1/p62, compared with siNON, treatment also decreased pS6 
levels (Figure 1- 7d and Figure 1- 9a). Based on these results, I speculated that mTOR 
signaling activation was important for hepatic differentiation induced by autophagy 
inhibition and intracellular p62 accumulation.  
Immunofluorescence results supported the significance of mTOR signaling for hepatic 
differentiation (Figure 1- 8a and b, Figure 1- 9b and c). At 2 wk after initiation of 
differentiation conditions by siATG5, some cells displayed low or negative CK19 staining, 
showing that they were differentiated toward hepatocytes. mTOR activation, as indicated 
by pS6 staining, primarily existed in CK19-negative cells. The pS6-positive cells had 
higher levels of p62 protein. While siATG5 increased numbers of p62- and pS6-positive 
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cells, siSQSTM1/p62 had the opposite effect (Figure 1- 8a, Figure 1- 9b). As shown in 
Figure 1- 9c, pS6-positive cells were nearly all albumin-positive under siNON treated 
control conditions. Treatment with siATG5 increased pS6- and albumin-positive cells, 
while siSQSTM1/p62 treatment decreased both (Figure 1- 8b, Figure 1- 9c).  
Rapamycin, an mTOR inhibitor, had several concentration-dependent effects. It 
inhibited pS6 signaling, without reducing p62 protein levels, decreased albumin and 
increased SOX9 levels (Figure 1- 10a). Rapamycin also decreased mRNA expression of 
the hepatocyte marker albumin, similar to the results of western blotting analysis (Figure 
1- 10b).  
These results suggested that mTOR signaling was significant for differentiation of 
LPCs into hepatocytes. 
4.5. mTOR activation by amino acids was significant for hepatic differentiation. 
I speculated that growth factors might not be significant as mTOR activators during 
hepatic differentiation of LPCs because, at higher concentrations of HGF, hepatic 
differentiation was suppressed, based on increased levels of CK19 and SOX9 (Figure 1- 
11a and b). Because leucine and glutamine are more potent activators of mTOR signaling 
than other amino acids, their effects on differentiation were investigated. Furthermore, 
the effects of branched chain amino acids (BCAAs) were also investigated, because 
previous reports showed that they were important for stimulating albumin synthesis 
through mTOR activation in hepatocytes (Ijichi et al., 2003; Nishitani et al., 2004; Okuno 
et al., 1995). Immunofluorescence (Figure 1- 12a) and western blotting (Figure 1- 12b) 
revealed that removal of various amino acids from the differentiation medium suppressed 
or delayed hepatic differentiation of LPCs, compared with in normal differentiation 
medium, based on decreased albumin and increased CK19 levels. Differentiation medium 
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containing higher concentrations of leucine promoted differentiation, as indicated by 
decreased CK19 by immunofluorescence (Figure 1- 13a). Western blotting (Figure 1- 
13b) gave similar results, showing decreased CK19 and SOX9. No effects on albumin 
levels were observed, but I speculated that the effects of leucine on albumin would be 
maximal anyway at the concentration (0.53 mM) in normal differentiation medium. 
qRT-PCR analysis supported the results from protein assessments (Figure 1- 12, Figure 1- 
13) and also demonstrated the significant effects of BCAA containing leucine on hepatic 
differentiation (Figure 1- 14) 
These results suggested that amino acids acted as mTOR activators for hepatic 
differentiation. 
4.6. Possibility of enhanced amino acid sensing of mTOR by increased 
intracellular p62 levels under hepatic differentiation conditions. 
Amino acid sensitivity of mTOR activation was examined in LPCs treated with siNON, 
siATG5 or siSQSTM1/p62. As shown in Figure 1- 15 a and b, the presence of leucine 
increased mTOR activation, based on pS6 staining in cells treated with siATG5. In 
contrast, mTOR activation by leucine was almost completely abolished under 
SQSTM1/p62 knockdown conditions. The results of western blotting were consistent with 
the immunofluorescence (Figure 1- 15c). Leucine-induced increases in p62 and in S6 
phosphorylation were observed under ATG5 knockdown. Furthermore, with 
siSQSTM1/p62 treatment, p62 was downregulated and leucine-induced S6 
phosphorylation was decreased. These results suggested that autophagy and intracellular 
p62 status influenced the amino acid sensitivity of mTOR activation. 
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5.  Discussion 
  Figure 1- 16 present a model based on my study, which lead to five major novel 
findings. First, inhibition of autophagy induced hepatic differentiation in LPCs. Second, 
alteration of intracellular p62 levels affected hepatic differentiation. Third, mTOR 
activation promoted hepatic differentiation. Fourth, amino acids are important for 
differentiation toward a hepatic phenotype, through mTOR activation. Fifth, the amino 
acid sensitivity of mTOR activation is dependent on autophagy and intracellular p62 
levels in LPCs. Together, these results suggest that p62 promotes amino acid sensitivity 
of the mTOR pathway and the differentiation of LPCs toward hepatocytes. 
  LPCs proliferate following chronic liver damage and numerous duct-like oval cells that 
could differentiate into either hepatocytes or bile ducts were observed around the portal 
vein in rodents with experimental liver injury (Lowes et al., 1999). EPCAM and CD133 
have been used as markers to isolate adult-type LPCs (Okabe et al., 2009; Suzuki et al., 
2008). Previous reports have indicated that large and small cell colonies were formed 
from cultured cells that were isolated as EPCAM- or CD133-positive. The large colonies 
were relatively committed toward hepatocytes, whereas the small colonies were 
committed toward cholangiocytes (Okabe et al., 2009; Suzuki et al., 2008). Isolation of 
cells expressing lower CD133 levels, among the EPCAM-positive cells by FACS 
appeared to select cells that were more committed toward hepatocytes in our study. 
Alternatively, it was suggested that these cells could be stem/progenitor-like cells derived 
from mature hepatocytes (Tarlow et al., 2014). 
  First, I examined the effects of autophagy inhibition on the hepatic differentiation of 
LPCs. I postulated that inhibition of autophagy by 3-MA or siATG5 would disturb 
intracellular homeostasis and impair hepatic differentiation in LPCs. Unexpectedly, 
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albumin levels were increased by autophagy inhibition, but these increased albumin 
levels were apparently not caused by inhibition of non-selective autophagic protein 
degradation. This was demonstrated by increased ALB mRNA and decreased CK19 
protein expression. LPCs have a smaller size and fewer intracellular organelles than 
mature hepatocytes. A previous study showed that the diameter of LPCs was 
approximately 10 μm, which is a half to a third of that of hepatocytes (Tarlow et al., 2014). 
It was recently proposed that autophagy might maintain fewer organelles such as 
mitochondria by degrading them, resulting in a smaller cell size and preventing LPC 
differentiation (Tarlow et al., 2014). 
  Next, I hypothesized that increased intracellular p62 was a candidate mechanism for 
hepatic differentiation by autophagy inhibition because immunological analyses 
indicated that p62 levels were elevated in well-differentiated HNF4α-positive cells. The 
results of our experiment using siSQSTM1/p62 confirmed that p62 is a critical mediator 
of hepatic differentiation, because p62 protein deficiency did not induce or promote 
differentiation.  
  p62 is an adaptor protein that regulates various physiological and pathological 
intracellular signaling pathways (Duran et al., 2004; Martin et al., 2006; Rodriguez et al., 
2006). Besides its function as an autophagy adaptor, p62 regulates osteoclastogenesis, T 
cell differentiation, and adipogenesis through various intracellular signaling pathways. 
Among the various functions of p62, I investigated its role in amino acid sensing via the 
mTOR pathway (Duran et al., 2011). mTOR activity is regulated by many intracellular 
mechanisms that sense the extracellular alterations in growth factors and amino acids. My 
pathway analysis demonstrated that the activity of mTOR pathway varied in accordance 
with p62 status. Other than PI3K–AKT pathway inactivation, no other signaling changes 
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were observed. 
  Generally, the mTOR pathway is activated through stimulation of the PI3K–AKT 
pathway in growth factor signaling. However, my results using siATG5 treatment, 
indicated that mTOR pathway activation was not associated with PI3K–AKT pathway 
activity. Therefore, I assumed that amino acids served as stimulators of mTOR signaling 
for differentiation. In fact, lower HGF concentrations promoted differentiation toward 
hepatocytes and removal of amino acids impaired or delayed differentiation. As reported 
previously, BCAAs prevented growth factor-induced hepatic tumor cell proliferation 
through mTOR activation and PI3K–AKT pathway inactivation because of the negative 
feedback from mTOR (Hagiwara et al., 2012). Furthermore, the same group of 
investigators reported that BCAAs also suppressed a hepatocellular cancer stem cell 
phenotype through a similar mechanism (Nishitani et al., 2013). From my results and the 
previously reported evidence, I speculated that mTOR activation by amino acids was 
important to suppress the stem cell phenotype and thereby, to promote differentiation 
toward hepatocytes. 
  Low BCAA/aromatic amino acid ratios reduced the biosynthesis and secretion of 
albumin in hepatocytes (Okuno et al., 1995) and were also associated with poor prognosis 
in patients with chronic liver disease (Steigmann et al., 1984). In addition, BCAAs are 
often used as a supplemental therapy to address protein malnutrition in patients with liver 
cirrhosis. BCAAs, particularly leucine, activated mTOR and regulated albumin synthesis, 
through mRNA translation in cultured rat hepatocytes (Ijichi et al., 2003; Okuno et al., 
1995). Glutamine is another potent amino acid for mTOR activation and in combination 
with leucine, significantly activated mTOR signaling (Duran et al., 2012). My results 
demonstrated that BCAAs, leucine, and glutamine were significant for mTOR activation 
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and hepatic differentiation in LPCs. I further observed that a combination of leucine and 
glutamine was more effective than either amino acid alone. To my knowledge, this is the 
first report that amino acids contribute to hepatic differentiation through mTOR pathway 
activation. 
  LPCs undergo major expansion following chronic liver damage. In rodent experimental 
liver injury models, oval cells containing LPCs, which can differentiate into either 
hepatocytes or bile ducts, appeared around the portal vein (Lowes et al., 1999). 
Furthermore, in human diseases, the extent of biliary-like progenitor cell proliferation 
was consistently correlated with the degree of clinical impairment (Lowes et al., 1999; 
Sancho-Bru et al., 2012). As recently reported, mature hepatocytes could 
transdifferentiate into ductal biliary epithelial cells (Michalopoulos et al., 2005; Sekiya 
and Suzuki, 2014). Hepatocytes were also shown to be transformed into a 
cholangiocarcinoma, which is a biliary-cell-like tumor (Sekiya and Suzuki, 2012; Sekiya 
and Suzuki, 2014). Furthermore, as recently reported, hepatocyte-to-duct conversion was 
reversible and hepatocyte-derived progenitors could differentiate back to hepatocytes in 
vivo (Tarlow et al., 2014). One characteristic of mature hepatocyte-derived progenitors 
was a relatively lower expression of EPCAM and CD133 compared with that in 
biliary-derived cells, as described recently (Tarlow et al., 2014). In my study, the 
CD133low population among EPCAM-positive non-parenchymal cells could differentiate 
toward hepatocytes whereas the CD133high population could not. These results suggest 
that the cells described in my study were hepatocyte-derived progenitors. 
  Considering that hepatocyte-to-duct conversion is reversible, and that 
hepatocyte-derived progenitors could differentiate back to hepatocytes, pharmacological 
agents that improve the efficacy of progenitor-to-hepatocyte conversion might be novel 
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treatments to improve hepatic function and outcomes in some chronic liver injuries. For 
example, a recent study demonstrated that expression of autophagy-related genes such as 
LC3B was increased in the cirrhotic liver compared with that in the non-cirrhotic liver. 
Furthermore, LC3B localization was consistent with the cholangiocyte and liver 
progenitor marker CK19, in humans and rodents (Hung et al., 2015). This study also 
revealed that inhibition of autophagy attenuated the ductular reaction and fibrosis in the 
liver in a drug-induced cirrhotic model. My study suggests that in addition to autophagy 
inhibition, mTOR pathway activation by amino acids or enhancement of the amino acid 
sensitivity of mTOR activity by regulating the interaction between p62 and mTOR could 
be an effective medical treatment for the cirrhotic liver by attenuating the ductular 
reaction and promoting hepatic differentiation of biliary-like progenitors. 
  In conclusion, inhibition of autophagy and increased intracellular p62 positively 
coordinated hepatic differentiation through mTOR pathway activation. Moreover, my 
findings indicate that amino acids are important for hepatic differentiation. These results 
help to clarify the process by which LPCs differentiate into hepatocytes. Pharmacological 
agents or other treatment methods that improve the efficacy of LPC differentiation to 
hepatocytes may help improve hepatic function and outcomes in chronic liver damage. 
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6.  Tables 
 
Table 1- 1. List of antibodies used in immunological assays 
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Table 1- 2. List of probes used in qRT-PCR 
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7.  Figures 
 
Figure 1- 1. Isolated mouse adult progenitor/stem cells (LPCs) from DDC-injured 
liver differentiated toward hepatocytes in vitro. 
(a) CK19+ cells underwent expansion in the livers of mice fed a DDC diet. Bars = 300 μm. 
(b) mRNA expression at different timepoints during DDC feeding. Expression levels at 
each timepoint were normalized to those in mice fed a normal diet and are means ± S.D. 
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of data from 4–5 mice. **, P < 0.01 versus normal diet, Student’s t-test. These differences 
remained significant after correction for multiple testing by Bonferroni's inequality 
method. (c) Representative FACS plots and gates (boxed areas) used for sorting 
“CD133-Alexa Fluor (AF) 488High or 488Low/EPCAM-APC+/Lineage-PE-” liver 
stem/progenitor cells (LPCs). FACS plot showing staining with isotype controls. AF488 
is on the right-hand side. (d) Cultured CD133Low/EPCAM+/Lineage- cells. Cells shown in 
the upper and lower panels are actively proliferating and confluent, respectively. Bars = 
200 μm. (e) LPCs from DDC-injured liver differentiated into a hepato-like phenotype in 
vitro. Representative fluorescence microscopy images before (left panels) and at 2 wk 
after (right panels) exposure to differentiation conditions. Green, red, and magenta 
staining indicate albumin, CK19 and HNF4α, respectively. Bars = 50 μm. 
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Figure 1- 2. Isolated mouse adult progenitor/stem cells (LPCs) from DDC-injured 
liver differentiated toward hepatocytes in vitro. 
(a) Ductular reactions were induced in mice with a DDC diet. Ductular structures 
consisting of EPCAM+ cells underwent expansion in the liver of mice fed the DDC diet. 
Bars = 300 μm. (b) mRNA expression at different timepoints under the hepatic 
differentiation conditions was analyzed by quantitative RT-PCR (qRT-PCR). Expression 
levels are shown as relative to those on day 1 after plating. Data are means ± S.D. of three 
wells at each timepoint. **, P < 0.01 versus day 1, Student’s t-test. These differences 
remained significant after correction for multiple testing by Bonferroni's inequality 
method. (c) Protein levels at different timepoints during hepatic differentiation were 
determined by western blotting. 
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Figure 1- 3. Inhibition of autophagy by 3-methyladenine (3-MA) induced hepatic 
differentiation in LPCs. 
Incubation with 0.3, 1 or 3 mM 3-MA was started on day 6 after plating under the 
differentiation conditions. Effects of 3-MA were analyzed by immunofluorescence at 1 
wk 3-MA treatment. (a) Representative fluorescence microscopy images at 1 wk 
treatment. Bars = 50 µm. (b) Intensities of fluorescence microscopy images were 
analyzed. The data are means ± S.D. for 24 fields of view. *, P < 0.05; **, P < 0.01, 
versus control group, Student’s t-test. Differences in albumin and HNF4α at 1 or 3 mM 
3-MA and CK19 at 3 mM 3-MA remained significant after correction for multiple testing 
by Bonferroni's inequality method. 
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Figure 1- 4. Inhibition of autophagy by ATG5 silencing induced hepatic 
differentiation in LPCs (western blotting). 
Cells were incubated with either a non-targeting siRNA (siNON) or ATG5-specific 
siRNA (siATG5) under the differentiation conditions. The effects of two types of siATG5 
were analyzed by western blotting at 2 wk treatment. 
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Figure 1- 5. Inhibition of autophagy by ATG5 silencing induced hepatic 
differentiation. 
(a) Either a non-targeting siRNA (siNON) or ATG5-specific siRNA (siATG5) was 
incubated with cells under the differentiation conditions. The effects of siATG5 were 
analyzed at 2 wk by immunofluorescence, as shown in representative fluorescence 
microscopy images in Figure 1- 6. Arbitrary ratios of albumin-positive cells to total cells 
and the absolute fluorescence intensities were analyzed. Data are means ± S.D. measured 
in 24 fields of view. **, P < 0.01, versus siNON, Student’s t-test. (b) Representative 
phase contrast microscopy image of differentiated LPCs after 2 wk siRNA treatment. Bar 
= 50 μm. (c) Effects of siATG5 on protein levels were analyzed by western blotting at 1 
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and 5 d and at 2 wk treatments. The relative densities of immunoreactive bands were 
quantified. Relative intensities are shown as ratios of the signals to those from cells given 
siNON at 1 d (CK19, ATG5, LC3, and βAct) or at 2 wk (ALB) (d) mRNA expression was 
analyzed by qRT-PCR at 5 d and 2 wk siATG5 treatment. Expression levels are shown as 
percentages of the values for cells treated with siNON, at 5 d. Data are means ± S.D. of 
three wells at each time point. **, P < 0.01, versus siNON at 5 d and ##, P < 0.01; #, P < 
0.05, versus siNON at 2 wk, Student’s t-test. Data shown in (a), (c), (d) and Figure 1- 4 
were from independent experiments. 
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Figure 1- 6. Inhibition of autophagy by ATG5 silencing induced hepatic 
differentiation in LPCs (immunofluorescence). 
Cells were incubated with either a non-targeting siRNA (siNON) or ATG5-specific 
siRNA (siATG5) under the differentiation conditions. Effect of siATG5(2) were analyzed 
at 2 wk treatment by immunofluorescence. Representative fluorescence microscopy 
images at 2 wk after the initiation of treatment. Green and magenta show albumin and 
HNF4α, respectively. Bars = 50 μm. 
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Figure 1- 7. Autophagic adaptor protein p62 significantly impacted hepatic 
differentiation. 
(a) Representative fluorescence microscopy images at 2 wk treatment with siNON or 
siATG5. Magenta, red, green and blue (DAPI) staining represent HNF4α, CK19, p62 and 
nuclei, respectively. (b) mRNA expression was analyzed by qRT-PCR at 2 wk treatment 
with either siNON or a SQSTM1/p62-specific siRNA (siSQSTM1/p62) during culture 
under the differentiation conditions. Expression levels are shown as relative to values in 
cells receiving siNON treatment. Data are means ± S.D. of three wells. **, P < 0.01; *, P 
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< 0.05 versus siNON, Student’s t-test. (c) Representative fluorescence microscopy 
images at 2 wk treatment with siNON and siSQSTM1/p62. Magenta, red, green and blue 
(DAPI) staining represent HNF4α, CK19, p62 and nuclei, respectively. (d) Effects of a 
siNON, siATG5, siSQSTM1/p62 or siATG5, given in combination with siSQSTM1/p62, 
on albumin, SOX9, ATG5, p62, S6 and pS6 protein levels was analyzed by western 
blotting at 2 wk treatment, during culture under hepatic differentiation conditions. 
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Figure 1- 8. Effect of siSQSTM1/p62 on hepatic differentiation of LPCs. 
Cells were incubated with either siNON or SQSTM1/p62-specific siRNA 
(siSQSTM1/p62) during culture under hepatic differentiation conditions for 2 wk. (a), (b) 
Representative fluorescence microscopy images at 2 wk treatment with siNON (left) and 
siSQSTM1/p62 (right). These images were obtained in experiments independent from 
those shown in Figure 3. Bars = 50 μm. (a) Green, red and cyan staining represent p62, 
CK19 and pS6, respectively. (b) Green, red and cyan staining represent albumin, CK19 
and pS6, respectively. (c) Intensity of fluorescence microscopy images. The data are 
means ± S.D. for 18 fields of view. **, P < 0.01, versus siNON, Student’s t-test. 
46 
 
 
Figure 1- 9. Identification of intracellular signaling, dependent on intracellular p62, 
involved in hepatic differentiation. 
(a) Total S6, pS6 (mTOR signaling), total AKT, pAKT (PI3k–AKT signaling), total 
ERK1/2, pERK1/2 (MAP kinase signaling), albumin, p62 and ATG5 levels were 
analyzed by western blotting following ATG5 knockdown (KD) or SQSTM1/p62 KD in 
LPCs cultured under hepatic differentiation conditions. (b), (c) Representative 
fluorescence microscopy images at 2 wk siNON, siATG5 or siSQSTM1/p62 treatment. 
Red and blue staining show CK19 and phosphorylated S6 protein, respectively. Green 
staining shows p62 (b) and albumin (c).  
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Figure 1- 10. mTOR signaling activation was important for hepatic differentiation. 
(a) LPCs treated with siATG5 were incubated with rapamycin, an mTOR inhibitor, at the 
indicated concentrations under differentiation conditions. Albumin, SOX9, p62, total S6, 
pS6 and ATG5 levels were analyzed by western blotting. The relative density of 
immunoreactive bands for ALB, S6 and pS6 were quantified and the pS6/S6 ratio was 
calculated. Values for ALB or pS6/S6 ratios are shown relative to those in cells treated 
with siNON. (b) Effects of rapamycin were analyzed by qRT-PCR, to determine mRNA 
expression of ALB and ATG5. Expression levels are shown as relative to values in cells 
receiving siNON treatment. Data are means ± S.D. of two wells. The Jonckheere-Terpstra 
trend test was used to examine ALB mRNA expression trends across varying 
concentrations of rapamycin. The trends for decreased ALB mRNA expression with 
increased concentrations of rapamycin were significant (P < 0.05). 
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Figure 1- 11. Effect of HGF on hepatic differentiation of LPCs. 
(a), (b) LPCs were cultured in differentiation medium containing 0.5 or 50 ng/mL HGF. 
(a) Representative fluorescence microscopy images for 0.5 or 50 ng/mL HGF treatment. 
Green, red and blue represent albumin, CK19 and nuclei, respectively. The arbitrary 
ratios of albumin- and CK19-positive cells to total cells and absolute fluorescence 
intensities were analyzed, as shown in right panels. Data are means ± S.D. for 27 fields of 
view. *, P < 0.05, Student’s t-test. (b) Albumin, SOX9 and CK19 protein levels, analyzed 
by western blotting, in cells subjected to 0.5 or 50 ng/mL HGF treatment. 
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Figure 1- 12. mTOR activation by amino acids was important for hepatic 
differentiation. 
(a), (b) LPCs were cultured in differentiation medium without (w/o) branched-chain 
amino acids (BCAAs), leucine (Leu), glutamine (Gln) or leucine plus glutamine. (a) 
Representative fluorescence microscopy images obtained in normal medium and medium 
without BCAA and leucine. Absolute fluorescence intensities for albumin or CK19 were 
analyzed, as shown in the right panel. Data are means ± S.D. obtained from 20 fields of 
view. **, P < 0.01; *, P < 0.05 versus normal medium, Student’s t-test. Differences of 
w/o BCAA, w/o Leu, w/o Leu/Gln versus normal for albumin and differences of w/o Gln 
or w/o Gln/Leu versus normal for CK19 remained significant after correction for multiple 
testing by Bonferroni's inequality method. (b) Albumin, CK19, SOX9 and 
phosphorylated S6 protein were analyzed by western blotting. 
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Figure 1- 13. Effect of leucine on hepatic differentiation of LPCs. 
(a) Effects of leucine on hepatic differentiation were investigated by culture in 
differentiation medium containing 4 mM leucine. Representative fluorescence 
microscopy images. Green, red and blue represent albumin, CK19 and nuclei, 
respectively. Absolute fluorescence intensity for albumin and CK19 were analyzed, as 
shown in middle panels. The data are means ± S.D. for 18 fields of view. *, P < 0.05, 
Student’s t-test. (b) Albumin, SOX9 and CK19 protein levels in cells cultured in normal 
medium or medium containing leucine (Leu), analyzed by western blotting. 
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Figure 1- 14. Effect of branched chain amino acids or leucine on hepatic 
differentiation of LPCs. 
Effect of branched chain amino acids (BCAA) or leucine (Leu) on hepatic differentiation 
was investigated by culture in differentiation medium without BCAA, without leucine or 
containing 4 mM leucine. mRNA expression levels of hepatocyte and stem 
cell/progenitor markers were analyzed by quantitative RT-PCR (qRT-PCR). Expression 
levels are relative to those in cells cultured in normal medium. Data are means ± S.D. of 
three wells, under each condition. 
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Figure 1- 15. Significance of enhanced amino acid sensitivity of mTOR by increased 
intracellular p62 levels. 
LPCs were treated with siNON, siATG5 or siSQSTM1/p62 under hepatic differentiation 
conditions for 2 wk. Differentiation medium containing 5 and10 mM nicotinamide was 
used for siATG5 and siSQSTM1/p62, respectively. Starvation was induced in Hank’s 
Balanced Salt Solution for 2 h followed by leucine treatment for 1 h. mTOR signaling 
was indicated by phosphorylation of S6 protein. (a) Representative fluorescence 
microscopy images. (b) Absolute fluorescence intensity for the pS6 staining. Data are 
means ± S.D. from 18 fields of view. **, P < 0.01; *, P < 0.05, Student’s t-test. These 
differences remained significant after correction for multiple testing by Bonferroni's 
inequality method. (c) pS6, S6, p62 and ATG5 were analyzed by western blotting. 
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Figure 1- 16. A model based on my findings. 
  
54 
 
Chapter 2: Role of JAG1-Notch Signaling in 
Epithelial-Mesenchymal Transition and Poor Prognosis 
in Colorectal Cancer 
 
1.  Abstract 
The importance of Notch signaling in colorectal cancer (CRC) development and 
progression has been presented previously. Increased expression of Jagged-1 (JAG1), a 
Notch ligand, in CRC has been demonstrated but the detailed prognostic significance of 
JAG1 in CRC has not been determined. JAG1 protein expression was examined by 
immunohistochemistry in 158 CRC specimens. Expression of JAG1 and E-cadherin and 
their association with clinicopathologic characteristics, overall survival (OS), and 
relapse-free survival (RFS) were evaluated. In vitro studies using compounds that 
regulate intracellular signaling and small interfering RNA that silence JAG1 were 
performed on a colon cancer cell line. JAG1 expression in cancerous tissues was weak, 
moderate, or strong in 32%, 36%, and 32% of specimens, respectively, and correlated 
with the histologic type and T stage. In multivariate analysis, JAG1 expression, histologic 
type, and lymphatic invasion were independently correlated with OS and RFS. The 
combination of high JAG1 expression and low E-cadherin expression had an additive 
effect toward poorer OS and RFS compared with the low JAG1/high E-cadherin 
expression subtype. A significant correlation between JAG1 expression and KRAS status 
was detected in groups stratified by high E-cadherin expression. In vitro studies 
suggested that the RAS-MEK-MAP kinase and Wnt pathways positively regulated JAG1 
expression. Gene silencing with siJAG1 indicated that JAG1 promotes epithelial to 
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mesenchymal transition and cell growth. Thus, high JAG1 expression is regulated by 
various pathways and is associated with a poor prognosis through promotion of epithelial 
to mesenchymal transition and cell proliferation or maintenance of cell survival in CRC. 
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2.  Introduction 
  The Notch signaling pathway is important for intestinal epithelial stem/progenitor cell 
self-renewal and differentiation (Sancho et al., 2015). Four Notch receptors (Notch 1–4) 
and five Notch ligands (DLL1, DLL3, DLL4, JAG1, and JAG2) have been identified 
(Hori et al., 2013). JAG1, like the other ligands, binds to Notch receptors and induces 
activation through the cleavage of Notch receptor by γ-secretase and subsequent release 
of the Notch intracellular domain (NICD). NICD can translocate to the nucleus where it 
forms a complex with a transcriptional regulator and activates the transcription of target 
genes such as the hairy and enhancer of split (HES) gene family (Hori et al., 2013). 
  Accumulating evidence has shown that deregulation of the Notch pathway plays a 
significant role in the progression of several malignancies. Furthermore, high JAG1 
expression levels are associated with enhanced progression and metastatic potential, 
recurrence, and poor overall survival (OS) in prostate cancer, breast cancer, glioma, head 
and neck cancers, and gastric cancer (Lin et al., 2010; Purow et al., 2005; Reedijk et al., 
2005; Santagata et al., 2004; Sethi et al., 2011; Yeh et al., 2009). 
  Additionally, Notch signaling is shown to be strongly activated in primary human 
colorectal cancer (CRC) and has an important role in the initiation and progression of 
CRC through the regulation of apoptosis, proliferation, angiogenesis, and cell migration 
(Arcaroli et al., 2016; Chu et al., 2010; Ozawa et al., 2014; Serafin et al., 2011; Sikandar 
et al., 2010; Sonoshita et al., 2011). Recent reports also indicate that JAG1 mediates the 
activation of Notch signaling in CRC and induces CRC progression (Dai et al., 2014; 
Guilmeau et al., 2010; Kim et al., 2013; Lu et al., 2013; Rodilla et al., 2009). Thus, the 
JAG1-Notch pathway has been regarded an attractive target for CRC therapy. 
  Although high JAG1 expression and the prognostic implications of Notch receptors in 
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cancer cells have been described (Arcaroli et al., 2016; Chu et al., 2010; Dai et al., 2014; 
Guilmeau et al., 2010; Kim et al., 2013; Ozawa et al., 2014; Paiva et al., 2015; Rodilla et 
al., 2009; Serafin et al., 2011), the prognostic significance of high JAG1 expression in 
CRC has not been determined. Therefore, I investigated the association of JAG1 protein 
expression with survival and recurrence in CRC by immunohistochemistry (IHC) using 
postoperative specimens and survey information on CRC prognosis collected at the 
research institute where I was engaged in this research. I also examined E-cadherin 
expression as a marker of EMT to evaluate a possible relationship between JAG1 and 
EMT in the prognostic role of these factors in CRC. To my knowledge, the detailed 
clinical results of this study provide the first report of the poor prognostic implication of 
high JAG1 expression in CRC patients. 
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3.  Methods 
3.1. Patients and specimens 
  A total of 158 consecutive patients with CRC who underwent surgical resection at the 
Department of Surgery and Science, Kyushu University Hospital, between 1995 and 
2002 were analyzed in this study. Histologic diagnosis was based on the World Health 
Organization Classification of Colorectal Carcinoma (Jass and Sobin, 1989). Pathologic 
staging was performed by the Department of Anatomic Pathology, Pathological Sciences, 
Kyushu University, Fukuoka, Japan, according to the tumor-node-metastasis 
classification system, as revised in 2002 (Sobin and Wittekind, 2002). Written informed 
consent was obtained from each patient prior to tissue acquisition. All fresh specimens 
were fixed in 10% formalin and embedded in paraffin. This study was conducted with the 
approval of the Ethics Committee of Kyushu University Hospital, Fukuoka, Japan, in 
accordance with the Declaration of Helsinki (Approval No. 27-193). 
3.2. Immunohistochemistry 
  Tumor sections were assessed immunohistochemically using rabbit polyclonal 
antibody against an intracellular region of JAG1 (sc-8303, 1:200; Santa Cruz 
Biotechnology, CA, USA), rabbit monoclonal antibody against an extracellular region of 
JAG1 (2155, 1:100; Cell Signaling Technology, MA, USA) and mouse monoclonal 
antibody against E-cadherin (M106, 1:1,000; Takara Bio; Kyoto, Japan) with the 
horseradish peroxidase-labeled polymer secondary antibody Envision+ system (Dako, 
CA, USA). Briefly, 4-µm sections were deparaffinized and dehydrated. For antigen 
retrieval, the specimens were pretreated in an autoclave at 120°C for 15 min in 0.01 M 
citrate buffer, pH 6.0. The sections were incubated for 30 min in 0.3% hydrogen 
peroxidase in absolute methanol to deactivate endogenous peroxidases. After blocking of 
nonspecific binding with 10% goat serum, the specimens were incubated at 4°C with 
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primary antibodies overnight. After washing with Tris buffered Saline (pH 7.4), the 
sections were incubated with the Envision+ system (Dako) for 1 hour at room temperature. 
Color was developed with liquid DAB chromogen in Tris-buffered saline (pH 7.4) 
containing hydrogen peroxide. The sections were counterstained with hematoxylin. The 
immunoreactivity score was determined as described by Allred et al (Allred et al., 1998). 
Scoring was performed by the study investigators, which included general pathologists. 
The score for JAG1 was determined by the three grades of intensity (‘weak’ for no or 
weak staining; ‘moderate’; or ‘strong’). The score for E-cadherin was determined by 
adding the grades for intensity (1 for no or weak; 2 for moderate; 3 for strong) and the 
percentage of positive cells (1: 0–1%; 2: 1–10%; 3: 10–33%; 4: 33–66%; and 5: 66–
100%). 
3.3. KRAS and BRAF sequencing 
  Mutation of KRAS at codons at 12 and 13 or BRAF at codon 600 was determined by 
direct sequencing as previously described (Nakanishi et al., 2013; Zhao et al., 2008). 
3.4. Microsatellite instability (MSI) analysis 
  MSI status was assessed using fluorescent-labeled primers and an automated DNA 
sequence, as previously described (Nakanishi et al., 2013; Zhao et al., 2008). Briefly, my 
collaborator amplified the microsatellite domain region by polymerase chain reaction 
(PCR) from cancerous and normal tissue. The fluorescent-labeled PCR product was 
loaded on ABI 310 sequencer and data was analyzed using Gene Scan software. High 
MSI (MSI-H) was defined as replication error in ≥2 markers. Low MSI (MSI-L) was 
defined as replication error in a single marker. 
3.5. Cell culture and reagents 
HCT-116 cells were purchased from the ATCC. HCT-116 p53−/− cells were kindly 
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provided by B. Vogelstein (Johns Hopkins University, Baltimore, MD, USA). These cells 
were authenticated in Ref. (Matsuoka et al., 2015). Caco-2 cells were purchased from the 
ECACC. Cell lines were passaged to prepare low-passage stocks, which were then 
cryopreserved in liquid nitrogen. Cell cultures were prepared from frozen stocks when the 
cells had undergone 1 month of continuous culture. HCT-116 cells were cultured in 
Dulbecco’s modified Eagle’s medium supplemented with 10% FBS, 100 U/mL penicillin, 
and 100 mg/mL streptomycin at 37°C in 5% CO2. Caco-2 cells were cultured in the same 
medium for HCT-116, but Non-Essential Amino Acids was added. CHIR99021 and 
PD0325901 were purchased from Cayman Chemical (MI, USA). 
3.6. Small interfering RNA (siRNA) studies 
siRNA studies were performed using siRNA against JAG1 (siJAG1) (oligo ID 
HSS176255) or siNON (oligo ID 12935–112) purchased from Invitrogen (MA, USA). 
The siRNAs were transfected into cells using Lipofectamine RNAiMAX transfection 
regent (Invitrogen) according to the manufacturer’s instructions. 
3.7. Western blot analysis 
  Cells were lysed in RIPA buffer. Lysates were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride 
membranes. The membranes were washed, blocked, and incubated with the primary 
antibody. After washing, the membranes were incubated with horseradish 
peroxidase-conjugated secondary antibodies and immunoreactive bands were visualized 
by enhanced chemiluminescence (Chemi-Lumi One Ultra: Nakarai Tesque, Kyoto, 
Japan) using an Amersham Imager 600 (GE Healthcare, Little Chalfont, UK). The 
antibodies used were rabbit polyclonal antibody against JAG1 (sc-8303, 1:200), rabbit 
monoclonal antibody against E-cadherin (3195, 1:1,000; Cell Signaling Technology, MA, 
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USA), rat monoclonal antibody against Snail (61368, 1:4,000; Active Motif, Inc., CA, 
USA), mouse monoclonal antibody against β-catenin (610153, 1:1,000; BD Biosciences, 
New Jersey, USA), rabbit polyclonal antibody against phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (9101, 1:1000; Cell Signaling Technology), rabbit polyclonal antibody 
against p44/42 MAPK (Erk1/2) (9102, 1:2000; Cell Signaling Technology), mouse 
monoclonal antibody against a-tubulin (T6199, 1:5,000; Sigma-Aldrich, MO, USA), and 
rabbit monoclonal antibody against glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (GTX100118, 1:5,000; GeneTex, CA, USA). 
3.8. Immunofluorescence analysis 
  Cells were fixed in 90% methanol at 4°C for 30 min. After permeabilization with 0.3% 
Triton X-100 and blocking with 3% bovine serum albumin, fixed cells were incubated 
with the following primary antibodies: rabbit polyclonal antibody against JAG1 (sc-8303, 
1:50, or 1:100), mouse monoclonal antibody against E-cadherin (M106, 1:1,000), and rat 
monoclonal antibody against Snail (61368, 1:500 or 1:1,000). After washing, the cells 
were incubated with Alexa Fluor-conjugated secondary antibodies (Molecular Probes, 
MA, USA) for visualization. 
3.9. Gene expression analysis 
Total RNA was extracted from cultured cells using an RNeasy Mini Kit (QIAGEN, 
Hilden, Germany) and reverse-transcribed using SuperScript III (ThermoFisher 
Scientific, MA, USA) according to the manufacturers’ instructions. qRT-PCR was 
performed using TaqMan enzyme and a StepOne plus PCR system (Applied Biosystems, 
MA, USA). The probes used were JAG1 (Hs00164982_m1), HES1 (Hs00172878_m1), 
CDH1 (Hs01023894_m1), VIM (Hs00958111_m1) from Applied Biosystems. 
Expression levels were normalized to expression of GAPDH. 
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3.10. Statistical analysis 
  All statistical calculations were performed using JMP Pro 10 statistical software (SAS 
Institute Japan, Tokyo, Japan). Relationships among the clinicopathologic factors and 
JAG1 and E-cadherin staining were analyzed using χ2 tests. Survival curves were plotted 
using the Kaplan–Meier method, and the log-rank test was used to determine associations 
between individual variables and survival. OS and relapse-free survival (RFS) were 
evaluated using the univariate or multivariate Cox proportional hazard model. Proportion 
data of recurrence were evaluated using the multivariate logistic regression model. 
Differences were considered significant at P < 0.05. 
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4.  Results 
4.1. JAG1 immunohistochemistry 
  Antibody against the intracellular region of JAG1 was used for immunohistochemical 
staining of CRC specimens. This antibody was relatively selective for JAG1 protein and 
had appropriate characteristics for analyzing the prognostic significance of JAG1 
expression in the cancerous tissue and endothelium by IHC, as shown in Figure 2- 1 and 
Figure 2- 2. 
Immunohistochemical analysis indicated that JAG1 was expressed by cancer cells and 
endothelium (Figure 2- 3). Weak (jcIHC-W), moderate (jcIHC-M), and strong (jcIHC-S) 
staining of cancerous tissues was detected in 51 (32%), 57 (36%), and 50 (32%) samples, 
respectively (Figure 2- 3, Table 2- 1). Weak (jeIHC-W), moderate (jeIHC-M), and strong 
(jeIHC-S) staining of endothelium was detected in 61 (39%), 54 (34%), and 43 (27%) 
samples, respectively (Figure 2- 3, Table 2- 1). 
4.2. Correlation of JAG1 expression in cancer cells or endothelium with 
clinicopathologic characteristics and recurrence 
  The correlation between JAG1 expression and clinicopathologic characteristics is 
shown in Table 2- 1. JAG1 expression in cancer cells was correlated with histologic type 
(P = 0.031) and T stage (P = 0.003). JAG1 expression in cancer cells was also 
significantly associated with JAG1 expression in endothelium (P < 0.001) and rate of 
recurrence (P = 0.009). Moreover, JAG1 expression in endothelium was correlated with 
lymph node metastasis (P = 0.035) and venous invasion (P = 0.039). Moderate intensity 
of staining in the endothelium tended to be associated with poorer characteristics than the 
other staining groups. 
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4.3. Analysis of the association between JAG1 expression and survival outcome 
The association between JAG1 expression in cancer cells and OS was evaluated in all 
patients (Figure 2- 4a). JAG1 expression was significantly associated with OS (P = 
0.006). Evaluation of the association between JAG1 expression and RFS in 131 patients 
with stage 0–III CRC (ST_0-III) showed that JAG1 expression was also significantly 
associated with RFS (Figure 2- 4b; P = 0.010). Analysis of the prognostic significance of 
JAG1 expression as indicated by the 5-year survival rate calculated by Kaplan–Meier 
estimates and hazard ratio analyzed using the Cox proportional hazard model revealed 
that higher expression of JAG1 is associated with a poorer survival rate and larger hazard 
ratio (Figure 2- 5). 
In univariate analysis for OS in all patients and for RFS in the ST_0-III subgroup, 
JAG1 expression was significantly correlated with both OS and RFS (Table 2- 2). In 
multivariate analysis, JAG1 expression, histologic type, and lymphatic invasion showed 
independent association with OS and RFS (Table 2- 2). Univariate analysis of the rate of 
recurrence in all patients by the logistic model (Table 2- 2) revealed a significant 
correlation of JAG1 expression with recurrence. Multivariate analysis showed that tumor 
stage and JAG1 expression were independently associated with recurrence (Table 2- 2). 
The association between JAG1 expression in endothelium and OS or RFS was also 
analyzed (Figure 2- 6 a and b). The 5-year survival rate calculated by the Kaplan–Meier 
estimate is shown in Figure 2- 6c and prognostic analysis of JAG1 expression by the Cox 
proportional hazard model is shown in Figure 2- 6d. High expression of JAG1 in 
endothelium was more strongly associated with RFS than with OS. 
4.4. Analysis of the association between JAG1 and E-cadherin expression 
  To investigate whether JAG1 expression is associated with the transition between 
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epithelial and mesenchymal characteristics, E-cadherin expression was analyzed as an 
epithelial marker by IHC (Figure 2- 7). E-cadherin expression was categorized by 
staining intensity (eIHC-In1–3) or the proportion of positive cells (eIHC-Pr1–5), as 
shown in Figure 2- 7 and Table 2- 3. High JAG1 expression (jcIHC-S vs. jcIHC-W/M) 
was significantly correlated with low E-cadherin expression in subgroup stratification by 
proportion (eIHC-Pr1-3 vs. eIHC-Pr4/5) (Table 2- 3, P = 0.023). 
4.5. Analysis of JAG1 expression in patient samples stratified by E-cadherin 
expression 
  A significant poor prognosis of low E-cadherin expression for OS was detected by 
log-rank test in analysis according to staining intensity of 1 vs. 2/3 (Figure 2- 8a, P = 
0.038). In this stratification, no correlation between JAG1 and E-cadherin expression was 
detected (Table 2- 3), therefore an additional prognostic impact of combined JAG1 and 
E-cadherin expression was expected. To investigate the significance of JAG1 expression 
on prognosis in samples stratified by intensity of E-cadherin staining, patients were 
divided into six groups as follows: (1) jcIHC-W/eIHC-In2/3; (2) jcIHC-M/eIHC-In2/3; 
(3) jcIHC-S/eIHC-In2/3; (4) jcIHC-W/eIHC-In1; (5) jcIHC-M/eIHC-In1; and (6) 
jcIHC-S/eIHC-In1 (Table 2- 4). The P value of the log-rank test for OS and RFS was 
0.011 and 0.001, respectively (Figure 2- 9 a and b). OS and RFS in jcIHC-M/eIHC-In2/3, 
jcIHC-S/eIHC-In2/3, jcIHC-M/eIHC-In1, and jcIHC-S/eIHC-In1 groups were 
significantly shorter than those of the jcIHC-W/eIHC-In2/3 group (Figure 2- 9 a–d). 
Specifically, the jcIHC-S/eIHC-In1 group showed the poorest outcome of all groups: 
3-year OS = 34.9% (HR = 10.08, 95% CI = 2.64–47.97, P = 0.001 [vs. 
jcIHC-W/eIHC-In2/3]); 3-year RFS = 33.3% (HR = 8.27, 95% CI = 2.49–31.67, P = 
0.001 [vs. jcIHC-W/eIHC-In2/3]). The relationship between JAG1 expression and RFS 
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was notable in the group with moderate or strong intensity of E-cadherin staining 
(eIHC-In2-3). Namely, the 3-year RFS rate in jcIHC-S/eIHC-In2/3 (45.6%) was much 
lower than that in jcIHC-M/eIHC-In2/3 (68%), whereas the 3-year OS rate in 
jcIHC-S/eIHC-In2/3 (74.3%) was almost the same as that for jcIHC-M/eIHC-In2/3 
(71.9%). This may indicate that high JAG1 expression is associated with shorter duration 
of recurrence rather than survival in the group with moderate or strong intensity of 
E-cadherin staining (eIHC-In2/3).  
The correlation of JAG1 expression in cancer cells stratified by E-cadherin expression 
with clinicopathologic characteristics, JAG1 expression in endothelium, KRAS, BRAF, 
and MSI status was evaluated (Table 2- 4, Table 2- 5 and Figure 2- 10). Because of the 
retrospective analysis, data on KRAS, BRAF, and MSI status were available for only 78, 
76, and 117 specimens of the 158 CRC patients, respectively. JAG1 expression in cancer 
cells stratified as high intensity of E-cadherin staining or large proportion of E-cadherin 
expression (eIHC-In2/3 or eIHC-Pr4/5) was significantly correlated with histologic type 
(Table 2- 4, Table 2- 5). And higher rate of KRAS mutation was observed in the 
jcIHC-S/eIHC-In2/3 group (48%) compared with the other groups (17% for 
jcIHC-W/eIHC-In2/3 and 23% for jcIHC-M /eIHC-In2/3) (Table 2- 4, Figure 2- 10). A 
significant correlation between JAG1 expression and KRAS status (P = 0.037, data not 
shown) was also observed in in the group with eIHC-Pr5 in stratification by eIHC-Pr1-4 
(n = 79) versus eIHC-Pr5 (n = 79) based on the proportion of E-cadherin expression. 
These result suggested that one of the mechanism for high JAG1 expression in CRC was 
the enhancement of KRAS and its downstream pathway. There were not significant 
correlation between JAG1 expression and BRAF or MSI status in the group stratified as 
strong and moderate intensity of E-cadherin staining (eIHC-In2/3). On the other hand, in 
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the group of the other stratification in E-cadherin (eIHC-In1), strong intensity of JAG1 
staining seemed to associate with MSI or BRAF status. However, I could not determine 
whether these associations for MSI or BRAF status were really significant because of too 
small sample size. 
4.6. Mechanism of increasing JAG1 expression and JAG1-dependent promotion 
of epithelial–mesenchymal transition and proliferation in a colon cancer cell line 
To investigate whether the KRAS-MEK-MAP kinase pathway regulates JAG1 
expression and the transition between epithelial and mesenchymal status, the effect of the 
MEK inhibitor PD0325901 was examined in the HCT-116 colon cancer cell line. 
Treatment with MEK inhibitor decreased expression of JAG1 and the mesenchymal 
marker SNAIL (Figure 2- 11 a, b). Conversely, E-cadherin expression was increased after 
inhibition of MEK (Figure 2- 11 a, b). The effect of the MEK inhibitor PD325901 on 
JAG1 expression and transition toward mesenchymal phenotype was also investigated by 
western blotting in the HCT-116 (KRAS G13D) and Caco-2 (KRAS wild) colon cancer 
cell lines (Figure 2- 12). HCT-116 cells have lower level of E-cadherin and higher level of 
JAG1, SNAIL, phosphorylated ERK1/2 in the control condition than in Caco-2 cells. 
Inhibition of MEK kinase lead to suppression of phosphorylated ERK1/2, JAG1 and 
SNAIL level in HCT-116. Conversely, increasing of E-cadherin expression was observed 
by inhibition of MEK in HCT-116. On the other hand, there were no or little change about 
JAG1, E-cadherin, and SNAIL expression by inhibition of MEK in Caco-2.  
I also detected the positive regulation of JAG1 expression and the EMT resulting from 
Wnt-β catenin pathway activation by the Glycogen synthase kinase (GSK) 3β inhibitor, 
CHIR-99021, in HCT-116 cells. Namely, treatment with CHIR-99021 increased JAG1 
and SNAIL expression and decreased E-cadherin expression (Figure 2- 11c). 
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The effect of JAG1 gene silencing on EMT in the colon cancer cell line was 
investigated using siJAG1. Western blot (Figure 2- 13a), qRT-PCR (Figure 2- 13b), and 
immunofluorescence (Figure 2- 14) analyses indicated that siJAG1 treatment increased 
expression of E-cadherin protein/mRNA, decreased expression of Snail protein and 
decreased expression of the mesenchymal marker vimentin mRNA compared with 
control siNON treatment. These results suggested that the colon cancer cell line transited 
into a more epithelial and less mesenchymal phenotype upon JAG1 gene silencing. 
I also examined the effect of siJAG1 on proliferation of HCT-116 cells and explored the 
possibility of crosstalk between the JAG1-Notch pathway and p53-related signaling by 
investigating the effects in HCT-116 p53−/− cells (p53KO). siJAG1 at the concentration of 
30 nM decreased JAG1 mRNA levels by more than 80% compared with siNON in both 
wild type (Wt) and p53KO cells (Figure 2- 13c). mRNA expression of HES1, one of the 
Notch signal target genes, was also decreased, suggesting suppression of intracellular 
Notch signaling (Figure 2- 13c). JAG1 and HES1 mRNA expression was significantly 
lower in p53KO than in Wt cells (Figure 2- 13c). JAG1 protein level was also suppressed 
by siJAG1 compared with siNON treatment (Figure 2- 13d). The lower expression level 
of JAG1 protein in p53KO than in Wt was concordant with the results of qRT-PCR 
analysis (Figure 2- 13c and d). Suppressed proliferation in Wt cells treated with siJAG1 
compared with cells treated with siNON was evident 2 days after initiation of treatment 
(Figure 2- 13e). No obvious effect of siJAG1 on proliferation in p53 KO cells was 
observed (Figure 2- 13e). 
  
69 
 
5.  Discussion 
To my knowledge, this study is the first report of the prognostic significance of JAG1 
expression in cancer cells from patients with CRC. Moreover, my data indicate a 
relationship between JAG1 and E-cadherin expression in the prognosis of CRC. 
Furthermore, I provide a novel insight into the correlation between KRAS status and 
JAG1 expression in CRC patients. Various studies have previously reported that a high 
JAG1 expression level was detected in cancer cells (Dai et al., 2014; Guilmeau et al., 
2010; Kim et al., 2013; Pannequin et al., 2009; Rodilla et al., 2009), and was correlated 
with tumor grade (Kim et al., 2013) in human patients. However, the prognostic 
significance of JAG1 expression in CRC cells has not been determined. My study 
demonstrated that higher JAG1 expression in cancer cells of CRC patients is associated 
with a poorer survival rate and an increased risk of recurrence, and that the combination 
of high JAG1 expression with low E-cadherin expression might lead to severely poor 
outcome. 
Three causes of the poor survival rate and increased risk of recurrence associated with 
high JAG1 expression have been proposed: increased cell proliferation or maintenance of 
survival, acquisition of a stem cell-like phenotype, and induction of an EMT-like 
phenotype in cancer cells. My study indicated that siRNA-mediated JAG1 gene silencing 
in a colon cancer cell line resulted in delayed cell proliferation with a subsequent decrease 
in cell number. Similar results have been reported previously (Dai et al., 2014; Kim et al., 
2013). The evidence from our in vitro study and the previous reports support the poor 
prognostic significance of high JAG1 expression in CRC. 
The second possibility involves JAG1 protein expression associated with the 
endothelium. I found that a high expression of JAG1 protein in the endothelium was 
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associated with a high expression of JAG1 protein in cancer cells and a poor prognosis, 
especially an increased recurrence risk. This result might be associated with the 
acquisition of a stem cell-like phenotype in cancer cells through Notch pathway 
activation by JAG1 secreted from the endothelium in CRC, as described previously (Lu et 
al., 2013). While my study did not explore the mechanisms of high JAG1 expression in 
the endothelium, some mechanisms were speculated from previous reports (Gopinathan 
et al., 2015; Johnston et al., 2009). For instance, proinflammatory cytokines such as 
TNF-α and IL6 are possible inducers of JAG1 expression in the endothelium. JAG1 
upregulation in colon cancer cell lines induced by forced Notch pathway activation also 
promotes stemness in the cancer cells themselves through positive feedback (Fender et al., 
2015). My study indicates that JAG1 expression in cancer cells was strongly correlated 
with JAG1 expression in the endothelium and that a stronger intensity of JAG1 staining in 
the endothelium and cancer cells was associated with a poor prognosis. Thus, JAG1 
secreted from the endothelium stimulates the Notch pathway in cancer cells, and JAG1 
expression in cancer cells might be upregulated dependent on the activity of Notch 
pathway itself in cancer cells. JAG1-Notch signaling in cancer cells may then be 
amplified through a positive feedback. These findings suggest that the transition toward a 
cancer stem cell-like phenotype in cancer cells is promoted through an interaction 
between the endothelium and cancer cells, mediated by JAG1, leading to a poorer 
prognosis in CRC patients. 
My study also demonstrates the significance of the JAG1-Notch pathway in EMT in 
human CRC. I detected a significant association between low E-cadherin and high JAG1 
expression in clinical CRC samples and found that high JAG1 expression in CRC cells 
correlated with the histologic type (decreased differentiation status) and T stage (deep 
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invasion) among the clinicopathologic characteristics. This correlation may be caused by 
an EMT-like phenomenon induced by JAG1-Notch pathway activation. Induction of an 
EMT-like phenotype in cancer cells might facilitate their exit from the original site, 
migration to distant locations, and survival in a new microenvironment (Kalluri and 
Weinberg, 2009; Peinado et al., 2007). Notch signaling was reported to mediate EMT 
thorough upregulation of Snail protein (Sahlgren et al., 2008). Moreover, forced Notch 
pathway activation was shown to increase JAG1 expression and promote EMT through a 
positive feedback in a colorectal cancer cell line (Fender et al., 2015). My in vitro study 
demonstrated that although siRNA-mediated JAG1 gene silencing induced transition to a 
more epithelial phenotype, activation of the Wnt pathway by inhibition of GSK-3β not 
only induced transition to a more mesenchymal phenotype but also increased JAG1 
expression as predicted from the previously reported circumstantial evidence (Guilmeau 
et al., 2010; Pannequin et al., 2009; Rodilla et al., 2009; Zhou et al., 2004). Previous 
studies and my in vitro study support the significant role of JAG1-Notch pathway 
activation in poor prognosis for human CRC through EMT induction. 
It was recently reported that concomitant Notch activation and p53 deletion triggers 
EMT and metastasis in a genetically engineered mouse model (Chanrion et al., 2014). I 
demonstrated that siJAG1 delayed or inhibited proliferation in the Wt cell line but had a 
less potent effect in a p53−/− cell line. Moreover, siJAG1 increased the expression of 
E-cadherin and decreased Snail protein in the Wt cell line, whereas a similar effect could 
not be detected in the p53−/− cell line (data not shown). These results indicate that 
JAG1-Notch signaling is important for the induction of an EMT-like phenotype as well as 
for proliferation through suppression of a p53-related pathway (Dotto, 2009). 
Alternatively, lower expression of JAG1 mRNA and protein in the p53−/− cell line 
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compared with that in Wt suggests a reciprocal relationship between JAG1 protein 
expression and p53 status (Dotto, 2009). This is an unexpected result and my studies 
could not validate a model in which concomitant Notch activation and p53 deletion 
triggers EMT (Chanrion et al., 2014). To address this issue, the effect of exogenous 
treatment with JAG1 in p53−/− cancer cells should be examined in the future. In the aspect 
of low JAG1 expression induced by p53 KO, my preliminary analysis in human clinical 
specimens indicated that low JAG1 expression was significantly associated with a high 
proportion of loss of heterozygosity in p53 status (data not shown). Thus, further studies 
on the association between JAG1 expression and p53 status in CRC patients might reveal 
the reciprocal relationship between p53 status and JAG1 expression. 
My findings also suggest that EMT is induced by mediators other than JAG1-Notch 
signaling as indicated by the weak correlation between the low staining intensity of 
E-cadherin and high JAG1 expression. Consequently, I demonstrated an additive impact 
of the combination of high JAG1 and low E-cadherin expression on prognosis and found 
that the poorest survival rate for both OS and RFS was indicated by this combination. I 
could not find any association between JAG1 expression and clinicopathologic 
characteristics in groups stratified by low E-cadherin expression, and therefore it might 
be important to identify which downstream pathway of JAG1-Notch leads to poorer 
prognosis in these groups. 
My study indicates a shorter recurrence free interval after surgery in patients with high 
JAG1 expression among the subgroup with an E-cadherin staining intensity of 2/3 
(Figure 2- 9), and shows that this phenomenon might be associated with a high rate of 
mutation in KRAS (Table 2- 4, Figure 2- 10). It was previously reported that MEK 
inhibition suppresses JAG1 expression induced by growth factors in head and neck 
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squamous cell carcinoma (Zeng et al., 2005). In my study, the MEK inhibitor suppressed 
JAG1 expression as well as SNAIL expression and upregulated E-cadherin in a colon 
cancer cell line with a KRAS mutation and an possibly activated MAP kinase pathway 
(Ahmed et al., 2013). Therefore, activation of the MAP kinase pathway by the KRAS 
mutation might be partially upstream of JAG1 expression in CRC. 
While this study presented a novel finding about the association among high JAG1 
expression, KRAS status, and prognostic significance in CRC, there are some limitations 
including retrospective nature, sample size, various stages, and lack of enough 
information regarding molecular status. Multicenter prospective studies that enable 
investigation of a large sample size could validate my findings in this study.  
In conclusion, this is the first report demonstrating the poor prognostic significance of 
high JAG1 expression in CRC. Moreover, my study revealed that low E-cadherin 
expression plays an additive role in the poor prognosis associated with high JAG1 
expression in CRC. The results of my in vitro study support the poor prognostic impact 
associated with high JAG1 expression in CRC and suggest clues for the potential 
mechanisms involved in the complicated regulation of JAG1 expression and JAG1-Notch 
pathway-induced cancer development, as illustrated by the model in Figure 2- 15 
Furthermore, this study implicates JAG1 and its related signaling pathways as a potential 
target for the development of new therapeutic approaches to reduce recurrence risk and 
cancer-related death after surgery for CRC. 
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6.  Tables 
Table 2- 1. Association between clinical characteristics and JAG1 expression in 
cancer cells and endothelium. 
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Table 2- 2. Univariate and multivariate analysis of factors associated with overall 
survival or relapse-free survival. 
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Table 2- 3. Associations between E-cadherin expression and clinical characteristics 
or JAG1 expression in cancer cells. 
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Table 2- 4. JAG1 expression in cancer cells stratified by E-cadherin expression 
(based on intensity of staining) and correlation with clinicopathologic 
characteristics, JAG1 expression in endothelium, and KRAS status 
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Table 2- 5. JAG1 expression in cancer cells stratified by E-cadherin expression 
(based on proportion of positive staining) and correlation with clinicopathologic 
characteristics, JAG1 expression in endothelium, and KRAS status 
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7.  Figures 
 
 
Figure 2- 1. Verification of anti-JAG1 antibody for immunohistochemical staining 
to analyze the prognostic value of JAG1 expression in human CRC. 
(a) Effect of small interfering RNA (siRNA) specific for JAG1 (siJAG1) on JAG1 protein 
expression in HCT-116 cells at 2 days after siJAG1 treatment analyzed by western 
blotting. JAG1 protein was detected as a protein of approximately 150 kDa that was 
knocked down by siJAG1. (b) Representative fluorescence microscopy images of 
HCT-116 cells 2 days after treatment with siNON or siJAG1. Blue staining indicates the 
nucleus and green staining shows JAG1 protein expression. Staining for JAG1 was 
observed in the plasma membrane and this signal was decreased by siJAG1 treatment. 
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Figure 2- 2. Comparison between anti-JAG1 antibodies for immunohistochemical staining in 
human CRC (original magnification × 50, scale bars represent 1 mm). 
(a, b) Examples of cancer cell staining with two types of anti-JAG1 antibody. Both 
antibodies showed a similar intensity and localization of staining. (c) Example of no or 
weak staining in cancer by two anti-JAG1 antibodies. Staining in the endothelium 
(arrowhead) was detected in the sample treated with antibody 1 (left panel) but not with 
antibody 2 (right panel). Antibody 1 detects the intracellular region of JAG1 protein 
whereas antibody 2 detects the extracellular region of JAG1 protein. The lack of staining 
for endothelium with antibody 2 suggests that the extracellular region of JAG1 was 
released by shedding, as described in reference (Lu et al., 2013). 
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Figure 2- 3. Representative immunohistochemical staining of JAG1 expression in human 
colorectal cancer tissues (original magnification ×100, scale bars represent 0.25 mm). 
(a) Example of cancer and endothelium tissue with weak intensity of staining (jcIHC-W, 
jeIHC-W). (b) Example of cancer and endothelium with moderate intensity of staining 
(jcIHC-M, jeIHC-M). (c) Example of cancer and endothelium with moderate and strong 
intensity of staining, respectively (jcIHC-M, jeIHC-S). (d) Example of cancer and 
endothelium with strong intensity of staining (jcIHC-S, jeIHC-S). (e) Example of poorly 
differentiated carcinoma with a strong intensity of staining. Representative each 5 regions 
in cancer or endothelium were indicated by open or filled arrow-heads, respectively. 
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Figure 2- 4. Prognostic significance of JAG1 expression in cancer cells by analysis of 
Kaplan–Meier estimates. 
(a) Kaplan–Meier estimates of 10-year overall survival (OS) in all CRC patients and (b) 
5-year recurrence-free survival (RFS) in patients except for Stage IV CRC according to 
staining intensity. Mod indicates moderate. 
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Figure 2- 5. Prognostic significance of JAG1 expression in cancer cells for all CRC 
patients and patients with stage 0–III disease (i.e., excluding stage IV). 
(a) Five-year survival rate calculated by analysis of Kaplan–Meier estimates as shown in 
Fig. 2 (W, Weak; M, Moderate; S, Strong). (b) Hazard ratio (HR) and 95% confidence 
interval (CI) for overall survival (OS) and relapse-free survival (RFS) analyzed by Cox 
proportional hazard model. Higher expression of JAG1 was associated with a larger 
hazard ratio. A significant HR for OS and RFS in all patients was detected for Mod vs. 
Weak (P = 0.005 for OS, P = 0.004 for RFS) and Strong vs. Weak (P = 0.001 for OS, P < 
0.001 for RFS) staining. A significant HR for OS and RFS in stages 0–III was detected for 
Mod vs. Weak (P = 0.050 for RFS) and Strong vs. Weak (P = 0.033 for OS, P = 0.002 for 
RFS) staining. 
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Figure 2- 6. Prognostic significance of JAG1 expression in endothelium by analysis 
of Kaplan–Meier estimates and Cox proportional hazards model. 
Kaplan–Meier estimates of (a) 10-year overall survival (OS) in all CRC patients, and (b) 
5-year recurrence-free survival (RFS) in CRC patients excluding stage IV, according to 
staining intensity. Mod indicates moderate staining. JAG1 expression was significantly 
associated with RFS (P = 0.002). (c) Five-year survival rate calculated by analysis of 
Kaplan–Meier estimates (W, Weak; M, Moderate; S, Strong). A lower survival rate was 
observed for RFS than for OS. (d) Hazard ratio and 95% confidence interval for Moderate 
or Strong vs. Weak staining intensity of JAG1 expression analyzed by Cox proportional 
hazards model. A significant HR for RFS was detected for Strong vs. Weak (P = 0.020 for 
all patients, P = 0.009 for stages 0–III). 
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Figure 2- 7. Representative immunohistochemical staining of E-cadherin expression 
in human CRC tissues (original magnification × 100, scale bars represent 0.25 mm). 
(a) Example showing proportion score 5 (eIHC-Pr5) and intensity score 3 (eIHC-In3) 
staining in cancer cells. (b) Example showing proportion score 4 (eIHC-Pr4) and intensity 
score 3 (eIHC-In3) staining in cancer cells. (c) Example of proportion score 3 (eIHC-Pr3) 
and intensity score 1 (eIHC-In1) staining in cancer cells. Intensity score 1 (eIHC-In1), 2 
(eIHC-In2), and 3 (eIHC-In3) for staining was detected in 39 (25%), 63 (40%), and 56 
(35%) samples, respectively. Proportion scale 1–5 (eIHC-Pr1–eIHC-Pr5) of positive cells 
was detected in seven (4%), 16 (10%), 21 (14%), 35 (22%), and 79 (50%) patients 
respectively (Table S1). 
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Figure 2- 8. Prognostic significance of E-cadherin expression by analysis of Kaplan–
Meier estimates. 
Kaplan–Meier estimates of (a) 5-year overall survival (OS) in all CRC patients and (b) 
5-year recurrence-free survival (RFS) according to staining intensity of E-cadherin. 
Prognostic significance for OS of E-cadherin expression in CRC was also analyzed by 
log-rank test in another stratification (data not shown). The p value of eIHC-In-1/2 vs. 
eIHC-In3, eIHC-Pr1/2/3 vs. eIHC-Pr4/5, and eIHC-Pr1/2/3/4 vs. eIHC-Pr5 was 0.281, 
0.194, and 0.157, respectively. E-cadherin expression was not significantly correlated 
with RFS. 
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Figure 2- 9. Prognostic significance of JAG1 expression in cancer cells stratified by 
E-cadherin expression (based on intensity of staining) shown by analysis of Kaplan–
Meier estimates and Cox proportional hazards model. 
(a, b) Kaplan–Meier estimate of 5-year OS (a) and 5-year RFS (b) in CRC patients 
according to staining intensity of JAG1 expression in cancer cells stratified by E-cadherin 
expression. jcIHC-W, -M, -S indicate weak, moderate, and strong intensity of staining of 
JAG1 expression in cancer cells, respectively. eIHC-In2/3 and eIHC-In1 indicate staining 
intensity of 2/3 and 1 for E-cadherin expression, respectively. (c) 3-year survival rate 
calculated by analysis of the Kaplan–Meier estimates shown in (a) and (b). (d) Hazard 
ratio (HR) and 95% confidence interval (CI) of JAG1 and E-cadherin expression 
analyzed by Cox proportional hazards model versus jcIHC-W/eIHC-In2/3 group. 
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Figure 2- 10. Correlation between KRAS status and JAG1 expression in CRC 
patients with staining intensity 2/3 for E-cadherin expression. 
Proportion of KRAS mutation as shown in Table 4 is presented as a red bar. Relationship 
between the KRAS status and JAG1 expression was statistically analyzed using the χ2 
test. 
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Figure 2- 11. Mechanisms of regulation of JAG1 expression based on in vitro study. 
(a) The effect of inhibition of RAS-MEK-MAP kinase pathway on JAG1 expression and 
induction of EMT-like phenotype was examined using the MEK inhibitor PD325901 in 
the colon cancer cell line HCT-116. In the left panel, blue staining indicates the nucleus 
and green staining indicates JAG1 protein. In the middle panel, blue staining indicates the 
nucleus and red staining indicates E-cadherin protein. In the right panel, blue, green, and 
red staining indicate the nucleus, SNAIL, and JAG1 protein, respectively. Scale bars 
represent 50 µm. (b) Fluorescence intensity of JAG1, Snail, and E-cadherin was analyzed. 
Data are presented as mean ± S.D. of 20 fields of view. *, P < 0.05, Student’s t-test. (c) 
Effects of Glycogen synthase kinase (GSK3) β inhibitor on JAG1 protein expression and 
EMT-like phenotype. JAG1, E-cadherin, and SNAIL protein expression was analyzed by 
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western blotting. 
 
Figure 2- 12. Effect of inhibition of RAS-MEK-MAP kinase pathway on JAG1, 
SNAIL and E-cadherin protein level in the cancer cell lines HCT-116 and Caco-2. 
JAG1, SNAIL, E-cadherin, and, total or phosphorylated ERK1/2 level were analyzed by 
western blotting in HCT-116 (KRAS G13D) and Caco-2 (KRAS wild) cells. PD325901 
was used to inhibit MEK activity. Activation of MAP kinase pathway was detected by the 
extent of phosphorylation of ERK1/2. 
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Figure 2- 13. Effect of JAG1 gene silencing on proliferation and epithelial 
mesenchymal transition (EMT)-like phenotype based on in vitro study. 
(a, b) Effect of small interfering RNA for JAG1 (siJAG1) on JAG1 expression and 
EMT-like phenotype. E-cadherin and SNAIL protein expression (a) or E-cadherin 
(CDH1) and vimentin (VIM) mRNA expression (b) were analyzed by western blotting 
and qRT-PCR respectively. Non-targeting siRNA (siNON) was used as a negative control. 
Expression levels of mRNA are indicated relative to expression with siNON treatment. 
Data are mean ± S.D. of nine wells. (c) Effect of siJAG1 on JAG1 and HES1 mRNA 
expression in p53−/− and wild type (Wt) HCT-116 cells. mRNA expression was presented 
as a ratio relative to expression in Wt cells treated with siNON in the left two panels. 
JAG1 mRNA expression in Wt or p53−/− cells treated with siJAG1 was also presented as 
a ratio relative to expression in Wt or p53-/- cells treated with siNON in the right panels. 
Data are mean ± S.D. of nine wells. (d) Effect of siJAG1 on JAG1 protein expression in 
p53−/− and Wt cells analyzed by western blotting. (e) Effect of siJAG1 on cell growth in 
p53−/− and Wt cells. siJAG1 treatment was initiated 2 days after plating. Data are 
presented as mean ± S.D. of six wells for each time point (result from three independent 
experiments). Statistical analysis was performed by Student’s t-test. * or #, P < 0.05. 
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Figure 2- 14. Effect of JAG1 gene silencing on epithelial–mesenchymal transition in 
HCT116 cancer cell line.  
Representative fluorescence microscopy images at 2 days of siNON and siJAG1 
treatment are shown. In the left panels, blue, green, and red staining indicates the nucleus, 
JAG1, and E-cadherin, respectively. In the right panels, blue, green, and red staining 
indicates the nucleus, SNAIL, and E-cadherin respectively. Scale bars represent 50 μm. 
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Figure 2- 15 Hypothesized mechanisms of cancer recurrence or death induced by 
JAG1-Notch pathway activation following increased JAG1 expression regulated by 
various factors.  
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General Discussion 
  In the two studies described above, I explored mechanisms for the transition of 
differentiation status in LPCs and CRC. Acquisition of a stem cell phenotype and/or 
mesenchymal characteristics seem to play an important role in epithelial cancer cell 
survival in severe environments such as starvation, hypoxia, attacks from immune cells 
or anticancer treatment, and escape from the severe environment. The acquisition of 
stem cell phenotype and/or mesenchymal characteristics could then contribute to drug 
resistance and/or radioresistance, tumor recurrence, and metastasis. Therefore, it seems 
important to understand the mechanisms underlying these transitions in epithelial cancer 
cells for overcoming the malignant phenotype. Moreover, exploring methods for 
converting these stem or mesenchymal status into a well-differentiated status potentially 
leads to new strategies for anticancer treatment. First, I investigated the role of 
autophagy and the related signaling pathways as the mechanism for transition towards 
differentiated hepatocytes in normal LPCs collected from a mouse liver injury model 
(part 1). Second, I evaluated the prognostic function of the JAG1-Notch pathway and 
EMT in CRC. Moreover, I investigated the related mechanism in vitro using a colon 
cancer cell line.  
  In the first part, I found that autophagy inhibition promotes hepatic differentiation in 
LPCs. Although normal stem/progenitor cells were used in my work, this new insight 
from my work could be beneficial for research on CSCs and for anticancer treatment in 
the liver. 
LPCs and/or cells similar to LPCs potentially derived from mature hepatocytes were 
isolated from the liver during oval-cell inducing injury in a rodent model with chronic 
liver injury. Tarlow et al. reported that 8.7–39.3% of cells expressing liver 
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stem/progenitor marker proteins were derived from mature hepatocyte in this DDC 
injury and that about 35% of these cells could differentiate into mature hepatocytes after 
about 4 weeks of recovery from a diet with DDC (Tarlow et al., 2014). Progenitors 
originated from hepatocytes were characterized by a relatively low expression of some 
stem/progenitor marker proteins such as EPCAM, CD133, and CK19 compared to cells 
of biliary origin (Tarlow et al., 2014). In my work, I isolated cells expressing EPCAM 
and divided these cells into two fractions by CD133 expression levels. Only cells with 
low expression levels of CD133 could undergo hepatic differentiation under the 
differentiation conditions in my work. While progenitors originating from cells with low 
CD133 expression levels were examined for the effect of autophagy inhibition on 
hepatic differentiation, the cells used in my work might have originated from mature 
hepatocytes. Oval-cell-inducing liver injuries that induce a ductular reaction are 
associated with an increased risk of primary liver cancers (Deugnier et al., 1993; Prior, 
1988; Tsukuma et al., 1993). Moreover, injured hepatocytes could dedifferentiate 
toward cells similar to LPCs under the ductular plasticity during oval-cell-inducing liver 
injury in chronic liver diseases, which could be relevant to liver cancer, particularly 
cholangiocarcinomas (Fan et al., 2012; Sekiya and Suzuki, 2012). Therefore, the new 
insight obtained from my work with regard to hepatic differentiation from LPCs might 
provide clues to clarify the mechanisms for ductular plasticity of hepatocytes during 
oval-cell-inducing injury. Further methods to differentiate hepatocytes from 
hepatocyte-derived progenitors may lead to new strategies for anticancer treatment in 
liver cancer.  
Recently, conversion of mature hepatocytes to bipotent stem/progenitor cells in vitro 
using a cocktail of small molecules was reported (Katsuda et al., 2017). These 
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chemically induced liver stem/progenitor cells (CLiPs) could differentiate into both 
mature hepatocytes and biliary epithelial cells. This report provides strong in vitro 
evidence supporting the mature hepatocyte reprogramming theory. The small molecules 
used in this paper were Y-27632 (Rho-associated, coiled-coil containing protein kinase 
[ROCK] inhibitor), A-83-01 (inhibitor of TGF-β type I receptor kinase (Anaplastic 
lymphoma kinase [ALK] 5), activin type IB receptor (ALK4), nodal type I receptor 
(ALK7), and CHIR99021 (GSK3 inhibitor), but the detailed molecular mechanisms for 
the mature hepatocyte plasticity have not been described yet. In the future, studying the 
role of autophagy, p62, and related signaling pathways for this mature hepatocyte 
reprogramming regimen as shown in the previous report could lead to further 
clarification of the detailed mechanism underlying ductular plasticity of hepatocytes 
during oval-cell-inducing injury. 
  Next, I would like to address the effect of amino acid-sensitive mTOR signaling 
pathway activation on hepatic differentiation in LPCs. It has been accepted that 
long-term treatment with BCAAs is an effective preventive treatment for improving the 
clinical outcome of cirrhotic patients by reducing the occurrence of liver failure 
(Kawaguchi et al., 2011; Marchesini et al., 2003; Muto et al., 2005). Moreover, recent 
reports describe that BCAA suppresses the incidence of hepatocellular carcinoma in 
cirrhotic patients (Muto et al., 2006; Nishikawa and Osaki, 2014; Tada et al., 2014). 
Supporting these findings, several mouse experiments have demonstrated that BCAAs 
reduce the incidence of chemically induced hepatocellular carcinoma (Iwasa et al., 
2010; Ohno et al., 2008; Takegoshi et al., 2017; Yoshiji et al., 2009). Moreover, recent 
report showed that suppression of mTOR complex (mTORC) 1 signaling in Raptor 
knockout mice rendered them more susceptible to chemically induced hepatic fibrosis 
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and hepatocellular carcinoma (Umemura et al., 2014). In my work, I indicated that 
amino acids, including BCAAs, play an important role for hepatic differentiation in 
LPCs. The new insight from my study that BCAA could promote a return from 
hepatocyte-derived progenitor to hepatocytes, might provide a possible mechanism for 
decreasing the incidence of hepatocellular carcinoma in chemically-induced or 
non-alcoholic steatohepatitis induced liver injury in a mouse model. Further studies are 
needed to clarify the association between the beneficial effect of BCAAs on the 
incidence of hepatocellular carcinoma and the promoting effect of BCAAs on hepatic 
differentiation in LPCs.  
  In the second part, I mainly investigated the association of JAG1 expression in 
cancerous tissues with prognostic impact, clinical characteristics, JAG1 expression 
levels in the endothelium, and EMT status (the extent of decreased E-cadherin 
expression) in CRC patients. I found that a high JAG1 expression in cancerous tissues 
was partly associated with EMT status. My study also suggested that JAG1 expression 
levels in cancer cells could be regulated exogenously by JAG1 itself expressed in the 
endothelium, and that JAG1 expression levels in cancer cells were also regulated 
intracellularly by Wnt-β catenin signaling, KRAS status, and p53 status in cancer cells. 
Moreover, my study also suggests that JAG1 expression levels are associated with EMT 
status in vitro. Therefore, although studies in the second part mainly concerned JAG1 
expression, I believe that increased JAG1 expression in cancer cells is nearly equivalent 
to acquisition of mesenchymal characteristics to a varying extent.  
  In my work, I obtained results about the correlation between both JAG1 expression 
levels in cancer cells and in the endothelium. This is important for understanding the 
underlying mechanism in malignancy of cancer cells through interactions between cancer 
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cells and the microenvironment. The Notch signaling pathway is important for normal 
intestinal epithelial stem/progenitor self-renewal and differentiation under healthy 
conditions (Sancho et al., 2015), and DLL1 and DLL4 function as physiological ligands 
for Notch receptors (Pellegrinet et al., 2011). Unlike in healthy conditions, JAG1 might 
be released as an angiocrine factor from endothelial cells and functions as a Notch ligand 
to induce the cancer stem cell phenotype in CRC (Lu et al., 2013). My work indicates that 
JAG1 expression in cancer cells is strongly correlated with its expression in the 
endothelium. This suggests that high JAG1 expression in the endothelium promotes 
acquisition of a cancer stem cell-like phenotype in cancer cells and leads to poor 
prognosis in humans. Further investigations will be needed to clarify the mechanisms of 
acquiring a stem cell phenotype and mesenchymal characteristics in cancer cells through 
the interaction between cancer cells and the surrounding tumor vasculature via JAG1 and 
other factors.  
  Mutations in the adenomatous polyposis coli (Apc) tumor suppressor gene are 
common and induce Wnt activation in CRC (85% in sporadic cancer), and tumors often 
acquire heterogeneous Wnt activity through an additional regulation. Mutations in the 
Apc gene, β-catenin, or in Wnt pathway regulatory proteins result in continuous 
activation of this signaling pathway (Haegebarth and Clevers, 2009). Thereby, I 
examined the effect of the GSK3β inhibitor CHIR-99021, on JAG1 and EMT marker 
expression in vitro. My investigation suggested that Wnt-β-catenin pathway activation 
increases JAG1 expression and induces EMT in CRC.  
  Inactivation of the p53 pathway by mutation of the tumor protein p53 (TP53) is the 
second key genetic step in colorectal cancer development (35-55% in sporadic cancer). 
Wild-type p53 mediates cell-cycle arrest and a cell-death checkpoint, which can be 
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activated by multiple cellular stresses (Markowitz and Bertagnolli, 2009). Moreover, 
p53 loss-of-function mutation seems to exacerbate EMT dependent on Notch pathway 
activation through increasing EMT-TF. This increased expression of EMT-TF occurs via 
a decrease in micro-RNA (miRNA)-34 levels that are positively regulated by p53 
(Chanrion et al., 2014; Kim et al., 2011). My work suggested that JAG1-Notch signaling 
is important for the transition toward a mesenchymal phenotype as well as for 
proliferation in a colon cancer cell line through suppression of the p53-related pathway. 
On the other hand, lower expression of JAG1 mRNA and protein in a p53-/- cell line than 
that in the Wt cell line was unexpected. This might indicate that deficiency of p53 reduces 
JAG1 expression due to unknown negative feedback mechanisms against facilitating 
activate notch signaling via the miRNA-34 related mechanism in cancer cells. To clarify 
the detailed mechanisms for this reciprocal regulation between JAG1 expression and 
p53 status, further investigations will be necessary in the future.  
  Oncogenic mutations of RAS and BRAF, which activate the MAPK signaling 
pathway, occur in 37% and 13% of colorectal cancers, respectively. My work suggested 
that epithelial populations with relatively high E-cadherin expression levels among 
CRC patients showed an association between JAG1 expression and the proportion of 
KRAS mutations. Recently, a large-scale consortium of leading scientists within the 
colorectal field reported a consensus molecular subtype (CMS) as four subtypes for 
CRC (Guinney et al., 2015). Among the four CMSs, CMS3 was reported as the subtype 
which had metabolic characteristics and was associated with KRAS mutations. 
Moreover, this subtype had more epithelial characteristics (Guinney et al., 2015). An 
association between the proportion of KRAS mutation and high JAG1 expression in the 
more epithelial group demonstrated in my work could predict that patients with KRAS 
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mutations among the CMS3 could show high JAG1 expression and a relatively more 
mesenchymal phenotype compared to patients without KRAS mutations even in the 
patients group with a more epithelial phenotype. In my work, a colon cancer cell line 
with KRAS mutations and high phosphorylated Erk1/2 levels was more sensitive to an 
MEK inhibitor with regard to JAG1 and Snail expression levels than a colon cancer cell 
line without KRAS mutation. Altogether, because it seems that a clinical subtype with 
more epithelial characteristics such as CMS3 has little or no exogenous influence from 
invading inflammatory or stromal cells as constituents of the microenvironment, the 
main determinants for malignant differentiation status of cancer cells in such a clinical 
subtype might be intracellular genetic/epigenetic alteration, which may be comparable 
to the monoculture situation in vitro. In this case, KRAS mutations could be one of the 
most potent genetic/epigenetic alterations for making the cancer cells more malignant.  
  In the general discussion, I address the role of the JAG1-Notch signaling pathway in 
liver cancer and CRC. Recent reports have provided evidence that Notch signaling is 
activated and oncogenic in hepatocellular carcinoma (Dill et al., 2013; Tschaharganeh et 
al., 2013; Villanueva et al., 2012), and might be important for the development of 
tumors following hepatitis B virus infection (Jeliazkova et al., 2013). Moreover, 
accumulating evidence supports a pro-tumorigenic role for Notch signaling in 
cholangiocarcinoma (Akhoondi et al., 2007; Jeliazkova et al., 2013; Zender et al., 2013). 
There seems to be a consensus that higher Notch signaling levels in liver progenitors 
favor bile duct differentiation over hepatocytic differentiation. Activation of Notch in 
these progenitors might promote cholangiocarcinoma. Thus, crosstalk between 
autophagy and Notch related signaling pathways with regards to stemness and hepatic 
differentiation in LPCs is of my interest. On the other hand, in CRC, although mutations 
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in NOTCH genes are rare, Notch signaling is constitutively activated in CRC, partly 
because of mutations in regulators of Notch signaling, including FBXW7 (Akhoondi et 
al., 2007; Babaei-Jadidi et al., 2011; Miyaki et al., 2009; Sancho et al., 2010; Zhu et al., 
2013). In addition, Notch activation has been linked to the regulation of varying 
signaling pathways such as Hippo/YAP signaling and miRNA related mechanisms as 
described in previous reports and in my work (Bu et al., 2013; Camargo et al., 2007; Fre 
et al., 2009; Kim et al., 2012; Kwon et al., 2011; Lu et al., 2013; Peignon et al., 2011; 
Rodilla et al., 2009; Tschaharganeh et al., 2013). Thus, Notch signaling may play a 
crucial role in the early stages of CRC development by controlling the fate of stem cells 
and cancer stem cells, and also in the later stages of tumor invasion and metastasis 
(Sonoshita et al., 2011). Altogether, the JAG1-Notch pathway signaling seems to be an 
important target for antitumor treatment in liver cancer (particularly 
cholangiocarcinoma) as well as CRC.  
  In conclusion, the findings obtained from my study in Part 1 suggest that LPCs or 
mature hepatocyte-derived LPCs-like cells could differentiate toward hepatocytes via 
autophagy inhibition and/or p62 dependent amino acid sensitive mTOR signaling 
pathway activation. This new finding may provide a clue to clarify the mechanism for 
biliary plasticity of hepatocytes (hepatocyte reprogramming theory), which is relevant 
to liver cancer, particularly cholangiocarcinoma. As shown in Part 2, JAG1 is a key 
Notch ligand in CRC and is connected with the differentiation status and the depth of 
invasion among the clinical characteristics in CRC patients. JAG1 expression levels are 
regulated by Wnt-β catenin, p53, and KRAS-MEK-Map kinase signaling pathway and 
are associated with EMT status. Therefore, my study suggests that JAG1 is an attractive 
target for novel anticancer treatments to suppress EMT, invasive potential, and 
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metastasis in CRC. These mechanisms for regulating the differentiation status in normal 
and cancer cells should provide significant insights for the development of novel and 
effective therapeutic approaches in cancers of the gastrointestinal tract and the liver.  
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